ANIL KSOODANIL K SOOD9048SOOD, ANIL KProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson21941283Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FRNature reviews. CancerRethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25.Nat Rev Cancer2011-09-23T00:00:002011Rethinking ovarian cancer: recommendations for improving outcomes.25476932Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma LNature communicationsmiR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014 Dec 05; 5:5671.Nat Commun2014-12-05T00:00:002014miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.25490449Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, B?rresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GBCancer cellCopy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014 Dec 08; 26(6):863-879.Cancer Cell2014-12-08T00:00:002014Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.1155 Pressler StHouston77030-3721TXAuthorship 1667011Authorship 1671261Authorship 1692216Authorship 1693396Authorship 16939411Authorship 1703992Authorship 1713322Authorship 1715911Authorship 1717434Authorship 1728553Authorship 1740757Authorship 1753265Authorship 17549012Authorship 1761621Authorship 1765827Authorship 1769252Authorship 17726418Authorship 17738515Authorship 17778014Authorship 17870314Authorship 17888216Authorship 1793773Authorship 17954018Authorship 1796439Authorship 17970215Authorship 18007915Authorship 1803602Authorship 18047514Authorship 18123915Authorship 18137410Authorship 18164017Authorship 1816586Authorship 1818639Authorship 1831827Authorship 1841298Authorship 18434515Authorship 18464412Authorship 1848076Authorship 18504718Authorship 18559012Authorship 1857554Authorship 1860238Authorship 1861608Authorship 18713610Authorship 1872913Authorship 1876873Authorship 18792216Authorship 18800424Authorship 1881171Authorship 18874419Authorship 18894434Authorship 18909522Authorship 1895229Authorship 1899057Authorship 1901352Authorship 1907205Authorship 19098611Authorship 1910496Authorship 19105410Authorship 1913853Authorship 19141612Authorship 1914777Authorship 1915232Authorship 1921512Authorship 1922229Authorship 19232119Authorship 19262515Authorship 19265515Authorship 19281922Authorship 19350017Authorship 19376911Authorship 19387616Authorship 1939236Authorship 19422522Authorship 19438910Authorship 19457513Authorship 1945773Authorship 19504534Authorship 1956555Authorship 196166128946861Sood AK, Sorosky JI, Krogman S, Anderson B, Benda J, Buller REGynecologic oncologySurgical management of cervical cancer complicating pregnancy: a case-control study. Gynecol Oncol. 1996 Dec; 63(3):294-8.Gynecol Oncol1996-12-01T00:00:001996Surgical management of cervical cancer complicating pregnancy: a case-control study.9305707Sood AK, Sorosky JI, Mayr N, Krogman S, Anderson B, Buller RE, Hussey DHCancerRadiotherapeutic management of cervical carcinoma that complicates pregnancy. Cancer. 1997 Sep 15; 80(6):1073-8.Cancer1997-09-15T00:00:001997Radiotherapeutic management of cervical carcinoma that complicates pregnancy.11013366Zhang SH, Sood AK, Sorosky JI, Anderson B, Buller RECancerPreservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva. Cancer. 2000 Oct 01; 89(7):1520-5.Cancer2000-10-01T00:00:002000Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva.11555717Mahavni V, Sood AKCurrent opinion in oncologyHormone replacement therapy and cancer risk. Curr Opin Oncol. 2001 Sep; 13(5):384-9.Curr Opin Oncol2001-09-01T00:00:002001Hormone replacement therapy and cancer risk.11733962Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller REGynecologic oncologyPapillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol. 2001 Dec; 83(3):501-3.Gynecol Oncol2001-12-01T00:00:002001Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma.11815969Lutgendorf SK, Anderson B, Ullrich P, Johnsen EL, Buller RE, Sood AK, Sorosky JI, Ritchie JCancerQuality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer. 2002 Jan 01; 94(1):131-40.Cancer2002-01-01T00:00:002002Quality of life and mood in women with gynecologic cancer: a one year prospective study.12712125Chun ML, Buekers TE, Sood AK, Sorosky JIAmerican journal of obstetrics and gynecologyPostoperative wound infection with Pasteurella multocida from a pet cat. Am J Obstet Gynecol. 2003 Apr; 188(4):1115-6.Am J Obstet Gynecol2003-04-01T00:00:002003Postoperative wound infection with Pasteurella multocida from a pet cat.12861147Bender DP, Sorosky JI, Buller RE, Sood AKAmerican journal of obstetrics and gynecologySerum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am J Obstet Gynecol. 2003 Jul; 189(1):113-7.Am J Obstet Gynecol2003-07-01T00:00:002003Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma.12878860Sood AK, Hendrix MJCancer biology & therapyThe complexity of tumor vascularity. Cancer Biol Ther. 2003 May-Jun; 2(3):257-8.Cancer Biol Ther2003-05-01T00:00:002003The complexity of tumor vascularity.16061675Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AKCancer researchTherapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005 Aug 01; 65(15):6910-8.Cancer Res2005-08-01T00:00:002005Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.16723288Sood AKGynecologic oncologyLocation matters. Gynecol Oncol. 2006 Jun; 101(3):378-9.Gynecol Oncol2006-06-01T00:00:002006Location matters.16914580Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchFocal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.Clin Cancer Res2006-08-15T00:00:002006Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.16951177Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, Dalgarno DC, Sawyer TK, Gallick GE, Sood AKCancer researchAntiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res. 2006 Sep 01; 66(17):8633-9.Cancer Res2006-09-01T00:00:002006Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.16969087Merritt WM, Thaker PH, Landen CN, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AKCancer biology & therapyAnalysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther. 2006 Oct; 5(10):1357-60.Cancer Biol Ther2006-10-31T00:00:002006Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.17634550Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchDual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res. 2007 Jul 15; 13(14):4209-17.Clin Cancer Res2007-07-15T00:00:002007Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.17716980Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AKThe Journal of biological chemistryStress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007 Oct 12; 282(41):29919-26.J Biol Chem2007-08-23T00:00:002007Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism.18519692Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DDCancer researchThe previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res. 2008 Jun 01; 68(11):4321-30.Cancer Res2008-06-01T00:00:002008The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression.18519766Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchHLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008 Jun 01; 14(11):3372-9.Clin Cancer Res2008-06-01T00:00:002008HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.18546616Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJAdvances in experimental medicine and biologyClassification of ovarian cancer: a genomic analysis. Adv Exp Med Biol. 2008; 622:23-33.Adv Exp Med Biol2008-01-01T00:00:002008Classification of ovarian cancer: a genomic analysis.18695710Nick AM, Sood AKNature clinical practice. OncologyThe ROC 'n' role of the multiplex assay for early detection of ovarian cancer. Nat Clin Pract Oncol. 2008 Oct; 5(10):568-9.Nat Clin Pract Oncol2008-08-12T00:00:002008The ROC 'n' role of the multiplex assay for early detection of ovarian cancer.19088029Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CDClinical cancer research : an official journal of the American Association for Cancer ResearchNuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008 Dec 15; 14(24):8143-51.Clin Cancer Res2008-12-15T00:00:002008Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.19395869Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AKCancer biology & therapyDual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.Cancer Biol Ther2009-06-24T00:00:002009Dual targeting of EphA2 and FAK in ovarian carcinoma.19788771Shinn EH, Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Li Y, Basen-Engquist KPalliative & supportive careAssociations with worry about dying and hopelessness in ambulatory ovarian cancer patients. Palliat Support Care. 2009 Sep; 7(3):299-306.Palliat Support Care2009-09-01T00:00:002009Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients.20009575Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AKCancer biology & therapyTargeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82.Cancer Biol Ther2010-02-16T00:00:002010Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.20145172Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AYClinical cancer research : an official journal of the American Association for Cancer ResearchFrequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010 Feb 15; 16(4):1119-28.Clin Cancer Res2010-02-09T00:00:002010Frequent downregulation of miR-34 family in human ovarian cancers.20564155Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK, Lubaroff DM, Lutgendorf SKCancerDiurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer. 2010 Sep 15; 116(18):4410-9.Cancer2010-09-15T00:00:002010Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer.20600809Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers TE, Goodheart MJ, Antoni MH, Sood AK, Lubaroff DMBrain, behavior, and immunityPreservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun. 2010 Nov; 24(8):1231-40.Brain Behav Immun2010-06-30T00:00:002010Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.21056906Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson VGynecologic oncologyDistinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011 Jan; 120(1):113-20.Gynecol Oncol2010-11-06T00:00:002010Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.21196359Carroll AR, Coleman RL, Sood AKFrontiers in bioscience (Scholar edition)Therapeutic advances in women's cancers. Front Biosci (Schol Ed). 2011 01 01; 3(1):82-97.Front Biosci (Schol Ed)2011-01-01T00:00:002011Therapeutic advances in women's cancers.21761359Saad AF, Hu W, Sood AKHormones & cancerMicroenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer. 2010 Dec; 1(6):277-90.Horm Cancer2010-12-01T00:00:002010Microenvironment and pathogenesis of epithelial ovarian cancer.22186256Cole SW, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1201-6.Clin Cancer Res2011-12-20T00:00:002011Molecular pathways: beta-adrenergic signaling in cancer.22520979Zand B, Coleman RL, Sood AKHematology/oncology clinics of North AmericaTargeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am. 2012 Jun; 26(3):543-63, viii.Hematol Oncol Clin North Am2012-06-01T00:00:002012Targeting angiogenesis in gynecologic cancers.22693353Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchMetronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res. 2012 Aug 01; 18(15):4114-21.Clin Cancer Res2012-06-12T00:00:002012Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.22871469Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, Sood AK, Ali-Fehmi RGynecologic oncologyOverexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol. 2013 Feb; 128(2):344-8.Gynecol Oncol2012-08-04T00:00:002012Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.22894933Wu CC, Yang TY, Yu CT, Phan L, Ivan C, Sood AK, Hsu SL, Lee MHCell cycle (Georgetown, Tex.)p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle. 2012 Sep 15; 11(18):3433-42.Cell Cycle2012-08-16T00:00:002012p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation.22895067Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu WCancer biology & therapyAurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 2012 Sep; 13(11):1034-41.Cancer Biol Ther2012-08-16T00:00:002012Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.23147994Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CNClinical cancer research : an official journal of the American Association for Cancer ResearchEndoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res. 2013 Jan 01; 19(1):170-82.Clin Cancer Res2012-11-12T00:00:002012Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.23912486Thaker PH, Sood AK, Ramondetta LMCancer biomarkers : section A of Disease markersImportance of adrenergic pathways in women's cancers. Cancer Biomark. 2013; 13(3):145-54.Cancer Biomark2013-01-01T00:00:002013Importance of adrenergic pathways in women's cancers.24379240Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen STCarcinogenesisEDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014 May; 35(5):1100-9.Carcinogenesis2013-12-30T00:00:002013EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.24486585Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchCross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55.Clin Cancer Res2014-01-31T00:00:002014Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.24604117Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, Xue F, Zhang WThe Journal of pathologyMiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014 Jul; 233(3):308-18.J Pathol2014-05-21T00:00:002014MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.24706848Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan SProceedings of the National Academy of Sciences of the United States of AmericaDynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A. 2014 Apr 08; 111(14):5331-6.Proc Natl Acad Sci U S A2014-03-24T00:00:002014Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.24709487Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman MEuropean journal of cancer (Oxford, England : 1990)Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48.Eur J Cancer2014-04-04T00:00:002014Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.25214561Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang WJournal of the National Cancer InstituteClinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep; 106(9).J Natl Cancer Inst2014-09-10T00:00:002014Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.Experimental TherapeuticsGynecological Oncology & Reproductive MedicineLeukemiaSystems BiologyMD AndersonROBERT CBAST JRROBERT C BAST JR8483BAST JR, ROBERT CProfessorGABRIELLOPEZGABRIEL LOPEZ8612LOPEZ, GABRIELProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorKAREN HLUKAREN H LU8836LU, KAREN HProfessorROBERTCOLEMANROBERT COLEMAN9184COLEMAN, ROBERTProfessorLINGEGOWDA SELANEREMANGALALINGEGOWDA SELANERE MANGALA9112MANGALA, LINGEGOWDA SELANEREInstructor33.46140.00518961681research areas16.580.0124122317coauthor of1236.09143.35260similar to11912selected publicationsAuthorship 2154962Authorship 2159722Authorship 2164241Authorship 2165242Authorship 2175982Authorship 2176783Authorship 2178331Authorship 2181651Authorship 2182051Authorship 2183785Authorship 2188726Authorship 2188754Authorship 2192011Authorship 2193302Authorship 2198126Authorship 2200517Authorship 2201485Authorship 2206259Authorship 2210141Authorship 2216144Authorship 2224273Authorship 2225199Authorship 2226539Authorship 2227682Authorship 22312227Authorship 22338510Authorship 2235191Authorship 2237113Authorship 2237849Authorship 22387412Authorship 22428516Authorship 22433915Authorship 2244253Authorship 22453610Authorship 22464612Authorship 2249231Authorship 22511312Authorship 2254452Authorship 2262106Authorship 2262807Authorship 22664321Authorship 2275556Authorship 2278381Authorship 22802214Authorship 2280274Authorship 22814216Authorship 2281585Authorship 2282032Authorship 22854520Authorship 22913424Authorship 2292563Authorship 22939216Authorship 22941919Authorship 22967114Authorship 23009110Authorship 2301798Authorship 2310754Authorship 2313189Authorship 2313202Authorship 23133612Authorship 2314101Authorship 2316173Authorship 2317204Authorship 2318031Authorship 2319442Authorship 23218016Authorship 23219111Authorship 23224015Authorship 2322862Authorship 23244118Authorship 23260917Authorship 2326623Authorship 23283911Authorship 23297037Authorship 23301912Authorship 2333749Authorship 2334495Authorship 2338512Authorship 2338658Authorship 23399512Authorship 2344256Authorship 23442614Authorship 23444630Authorship 2345397Authorship 23454413Authorship 2345732Authorship 2346219Authorship 23463032Authorship 2346746Authorship 23469811Authorship 23479810Authorship 2348096Authorship 23483112Authorship 23511838700537Skilling JS, Sood A, Niemann T, Lager DJ, Buller REOncogeneAn abundance of p53 null mutations in ovarian carcinoma. Oncogene. 1996 Jul 04; 13(1):117-23.Oncogene1996-07-04T00:00:001996An abundance of p53 null mutations in ovarian carcinoma.9067268Sood AK, Skilling JS, Buller RECancer researchOvarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res. 1997 Mar 15; 57(6):1047-9.Cancer Res1997-03-15T00:00:001997Ovarian cancer genomic instability correlates with p53 frameshift mutations.9266580Sorosky JI, Sood AK, Buekers TEObstetrics and gynecology clinics of North AmericaThe use of chemotherapeutic agents during pregnancy. Obstet Gynecol Clin North Am. 1997 Sep; 24(3):591-9.Obstet Gynecol Clin North Am1997-09-01T00:00:001997The use of chemotherapeutic agents during pregnancy.9454655Olson JK, Sood AK, Sorosky JI, Anderson B, Buller REGynecologic oncologyTaxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol. 1998 Jan; 68(1):25-8.Gynecol Oncol1998-01-01T00:00:001998Taxol hypersensitivity: rapid retreatment is safe and cost effective.10050867Buller RE, Sood AK, Lallas T, Buekers T, Skilling JSJournal of the National Cancer InstituteAssociation between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst. 1999 Feb 17; 91(4):339-46.J Natl Cancer Inst1999-02-17T00:00:001999Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.10831976Sood AK, Sorosky JI, Mayr N, Anderson B, Buller RE, Niebyl JObstetrics and gynecologyCervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes. Obstet Gynecol. 2000 Jun; 95(6 Pt 1):832-8.Obstet Gynecol2000-06-01T00:00:002000Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes.10933045Sood AK, Sorosky JI, Squatrito RC, Skilling JS, Anderson B, Buller RENeoplasia (New York, N.Y.)Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies. Neoplasia. 1999 Jun; 1(2):118-22.Neoplasia1999-06-01T00:00:001999Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.11002237Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JICancerQuality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer. 2000 Sep 15; 89(6):1402-11.Cancer2000-09-15T00:00:002000Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer.11030246Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller REJournal of the American College of SurgeonsLongterm central venous access in gynecologic cancer patients. J Am Coll Surg. 2000 Oct; 191(4):403-9.J Am Coll Surg2000-10-01T00:00:002000Longterm central venous access in gynecologic cancer patients.11263940Lowe MP, Ault KA, Sood AKGynecologic oncologyRecurrent carcinoma in situ of a neovagina. Gynecol Oncol. 2001 Mar; 80(3):403-4.Gynecol Oncol2001-03-01T00:00:002001Recurrent carcinoma in situ of a neovagina.11290546Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJThe American journal of pathologyMolecular determinants of ovarian cancer plasticity. Am J Pathol. 2001 Apr; 158(4):1279-88.Am J Pathol2001-04-01T00:00:002001Molecular determinants of ovarian cancer plasticity.11303196Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AKAmerican journal of obstetrics and gynecologyp53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol. 2001 Apr; 184(5):891-902; discussion 902-3.Am J Obstet Gynecol2001-04-01T00:00:002001p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.11309330Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PAClinical cancer research : an official journal of the American Association for Cancer ResearchThe p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res. 2001 Apr; 7(4):831-8.Clin Cancer Res2001-04-01T00:00:002001The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.11919241Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda JJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7.J Clin Oncol2002-04-01T00:00:002002Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.12209725Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AKCancerVascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer. 2002 Aug 15; 95(4):808-15.Cancer2002-08-15T00:00:002002Vascular endothelial growth factor and social support in patients with ovarian carcinoma.12231537Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJClinical cancer research : an official journal of the American Association for Cancer ResearchThe paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002 Sep; 8(9):2924-32.Clin Cancer Res2002-09-01T00:00:002002The paradoxical expression of maspin in ovarian carcinoma.14754706Eichholz AC, Van Voorhis BJ, Sorosky JI, Smith BJ, Sood AKObstetrics and gynecologyOperative note dictation: should it be taught routinely in residency programs? Obstet Gynecol. 2004 Feb; 103(2):342-6.Obstet Gynecol2004-02-01T00:00:002004Operative note dictation: should it be taught routinely in residency programs?15295395Frausto SD, Geisler JP, Fletcher MS, Sood AKAmerican journal of obstetrics and gynecologyLate recurrence of juvenile granulosa cell tumor of the ovary. Am J Obstet Gynecol. 2004 Jul; 191(1):366-7.Am J Obstet Gynecol2004-07-01T00:00:002004Late recurrence of juvenile granulosa cell tumor of the ovary.15297418Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004 Aug 01; 10(15):5145-50.Clin Cancer Res2004-08-01T00:00:002004EphA2 expression is associated with aggressive features in ovarian carcinoma.15447993Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JIClinical cancer research : an official journal of the American Association for Cancer ResearchSequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6080-5.Clin Cancer Res2004-09-15T00:00:002004Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.15954082Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DMCancerPsychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005 Jul 15; 104(2):305-13.Cancer2005-07-15T00:00:002005Psychosocial factors and interleukin-6 among women with advanced ovarian cancer.16000591Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchAntivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res. 2005 Jul 01; 11(13):4923-33.Clin Cancer Res2005-07-01T00:00:002005Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.16221381Kamat AA, Sood AKCurrent oncology reportsThe merits of vascular targeting for gynecologic malignancies. Curr Oncol Rep. 2005 Nov; 7(6):444-50.Curr Oncol Rep2005-11-01T00:00:002005The merits of vascular targeting for gynecologic malignancies.16361572Halder J, Landen CN, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchFocal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8829-36.Clin Cancer Res2005-12-15T00:00:002005Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.16380413Han LY, Landen CN, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AKJournal of clinical oncology : official journal of the American Society of Clinical OncologyPreoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):755-61.J Clin Oncol2005-12-27T00:00:002005Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.16428474Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SWClinical cancer research : an official journal of the American Association for Cancer ResearchStress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006 Jan 15; 12(2):369-75.Clin Cancer Res2006-01-15T00:00:002006Stress hormone-mediated invasion of ovarian cancer cells.16551853Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Han L, Gershenson DM, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchThe clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006 Mar 15; 12(6):1707-14.Clin Cancer Res2006-03-15T00:00:002006The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.16750560Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller AGynecologic oncologyPreoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006 Nov; 103(2):512-7.Gynecol Oncol2006-06-05T00:00:002006Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.16862152Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AKNature medicineChronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.Nat Med2006-07-23T00:00:002006Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.17154180Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AKCancerEphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007 Jan 15; 109(2):332-40.Cancer2007-01-15T00:00:002007EphA2 overexpression is associated with angiogenesis in ovarian cancer.17191357Sood AKJournal of postgraduate medicineSecond look laparotomy for ovarian germ cell tumors: to do or not to do? J Postgrad Med. 2006 Oct-Dec; 52(4):246-7.J Postgrad Med2006-10-01T00:00:002006Second look laparotomy for ovarian germ cell tumors: to do or not to do?17312398Thaker PH, Lutgendorf SK, Sood AKCell cycle (Georgetown, Tex.)The neuroendocrine impact of chronic stress on cancer. Cell Cycle. 2007 Feb 15; 6(4):430-3.Cell Cycle2007-02-09T00:00:002007The neuroendocrine impact of chronic stress on cancer.17353927Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PSBritish journal of cancerThe receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer. 2007 Apr 10; 96(7):1083-91.Br J Cancer2007-03-13T00:00:002007The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.17545551Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchCurcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007 Jun 01; 13(11):3423-30.Clin Cancer Res2007-06-01T00:00:002007Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.17643954Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, DeGeest K, Sood AK, Lubaroff DMBrain, behavior, and immunityPositive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun. 2008 Jan; 22(1):65-73.Brain Behav Immun2007-07-23T00:00:002007Positive psychosocial factors and NKT cells in ovarian cancer patients.17909042Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AKCancer researchAntitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45.Cancer Res2007-10-01T00:00:002007Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.17974982Landen CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AKCancer researchNeuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007 Nov 01; 67(21):10389-96.Cancer Res2007-11-01T00:00:002007Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.18268546Spannuth WA, Sood AK, Coleman RLNature clinical practice. OncologyAngiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008 Apr; 5(4):194-204.Nat Clin Pract Oncol2008-02-12T00:00:002008Angiogenesis as a strategic target for ovarian cancer therapy.18632639Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AKCancer researchClinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.Cancer Res2008-07-15T00:00:002008Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.18638541Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AKBrain, behavior, and immunityNeuroendocrine modulation of cancer progression. Brain Behav Immun. 2009 Jan; 23(1):10-5.Brain Behav Immun2008-06-27T00:00:002008Neuroendocrine modulation of cancer progression.18779606Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA, Cole S, Sood AK, Lubaroff DMJournal of clinical oncology : official journal of the American Society of Clinical OncologyInterleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008 Oct 10; 26(29):4820-7.J Clin Oncol2008-09-08T00:00:002008Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.19029832Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RCCell cycle (Georgetown, Tex.)Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle. 2008 Dec; 7(23):3747-58.Cell Cycle2008-12-16T00:00:002008Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.19470734Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.Clin Cancer Res2009-05-26T00:00:002009Therapeutic Targeting of ATP7B in Ovarian Carcinoma.19847298Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CDPloS oneThe ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 2009 Oct 22; 4(10):e7502.PLoS One2009-10-22T00:00:002009The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment.20109724Sood AK, Coleman RLGynecologic oncologyTargeted therapy in gynecologic oncology: biology, strategy, and assessment. Gynecol Oncol. 2010 Feb; 116(2):155-6.Gynecol Oncol2010-02-01T00:00:002010Targeted therapy in gynecologic oncology: biology, strategy, and assessment.20179193Merritt WM, Bar-Eli M, Sood AKCancer researchThe dicey role of Dicer: implications for RNAi therapy. Cancer Res. 2010 Apr 01; 70(7):2571-4.Cancer Res2010-02-23T00:00:002010The dicey role of Dicer: implications for RNAi therapy.20226736Stone RL, Sood AK, Coleman RLThe Lancet. OncologyCollateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010 May; 11(5):465-75.Lancet Oncol2010-03-10T00:00:002010Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.20371710Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AKMolecular cancer therapeuticsBridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010 Apr; 9(4):985-95.Mol Cancer Ther2010-04-06T00:00:002010Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.20388851Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70.Clin Cancer Res2010-04-13T00:00:002010EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.20430760Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari MCancer researchSustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96.Cancer Res2010-05-01T00:00:002010Sustained small interfering RNA delivery by mesoporous silicon particles.20682653Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AKMolecular cancer therapeuticsConverging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.Mol Cancer Ther2010-08-03T00:00:002010Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.20889728Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AKMolecular cancer therapeuticsTargeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99.Mol Cancer Ther2010-10-01T00:00:002010Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.20927342Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka TPloS oneIdentification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One. 2010 Sep 30; 5(9).PLoS One2010-09-30T00:00:002010Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting.21421858Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RKClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011 Apr 15; 17(8):2250-9.Clin Cancer Res2011-03-18T00:00:002011Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.21472135Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AKNeoplasia (New York, N.Y.)Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011 Apr; 13(4):309-19.Neoplasia2011-04-01T00:00:002011Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.21627858Rupaimoole R, Han HD, Lopez-Berestein G, Sood AKChinese journal of cancerMicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011 Jun; 30(6):368-70.Chin J Cancer2011-06-01T00:00:002011MicroRNA therapeutics: principles, expectations, and challenges.21753153Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CNClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85.Clin Cancer Res2011-07-13T00:00:002011Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.21989071Jackson DB, Sood AKNature reviews. Clinical oncologyPersonalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol. 2011 10 11; 8(12):735-41.Nat Rev Clin Oncol2011-10-11T00:00:002011Personalized cancer medicine--advances and socio-economic challenges.22021459Lutgendorf SK, Sood AKPsychosomatic medicineBiobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med. 2011 Nov-Dec; 73(9):724-30.Psychosom Med2011-10-21T00:00:002011Biobehavioral factors and cancer progression: physiological pathways and mechanisms.22028766Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LMPloS oneNeuropilin-2 mediated ?-catenin signaling and survival in human gastro-intestinal cancer cell lines. PLoS One. 2011; 6(10):e23208.PLoS One2011-10-20T00:00:002011Neuropilin-2 mediated ?-catenin signaling and survival in human gastro-intestinal cancer cell lines.22184398Sood AK, Coleman RL, Ellis LMJournal of clinical oncology : official journal of the American Society of Clinical OncologyMoving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):345-7.J Clin Oncol2011-12-19T00:00:002011Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer.22307563Melhem-Bertrandt A, Sood AKCancer prevention research (Philadelphia, Pa.)New directions in reducing stress effects on cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):147-9.Cancer Prev Res (Phila)2012-02-01T00:00:002012New directions in reducing stress effects on cancer.22585855Wu SY, Sood AKCancer discoveryNew roles opined for OPCML. Cancer Discov. 2012 Feb; 2(2):115-6.Cancer Discov2012-02-01T00:00:002012New roles opined for OPCML.22728325Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AKBrain, behavior, and immunityNeuroendocrine influences on cancer progression. Brain Behav Immun. 2013 Mar; 30 Suppl:S19-25.Brain Behav Immun2012-06-21T00:00:002012Neuroendocrine influences on cancer progression.22802321Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Zimmerman MB, Penedo FJ, Lucci JA, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole SW, Sood AKJournal of clinical oncology : official journal of the American Society of Clinical OncologySocial influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol. 2012 Aug 10; 30(23):2885-90.J Clin Oncol2012-07-16T00:00:002012Social influences on clinical outcomes of patients with ovarian cancer.22870317Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters LPloS oneDepressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012; 7(8):e42324.PLoS One2012-08-01T00:00:002012Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.22884960Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, Slavich GM, Sood AK, Lutgendorf SKBrain, behavior, and immunityCortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun. 2013 Mar; 30 Suppl:S126-34.Brain Behav Immun2012-08-05T00:00:002012Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability.22922531Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AKGynecologic oncologyA phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43.Gynecol Oncol2012-08-23T00:00:002012A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.22970210Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang LPloS oneGenomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One. 2012; 7(9):e44399.PLoS One2012-09-06T00:00:002012Genomic DNA copy-number alterations of the let-7 family in human cancers.23008289Bottsford-Miller JN, Coleman RL, Sood AKJournal of clinical oncology : official journal of the American Society of Clinical OncologyResistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012 Nov 10; 30(32):4026-34.J Clin Oncol2012-09-24T00:00:002012Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.23321064Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RKGynecologic oncologyA phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.Gynecol Oncol2013-01-13T00:00:002013A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.23344261Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SCClinical cancer research : an official journal of the American Association for Cancer ResearchIdentification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20.Clin Cancer Res2013-01-23T00:00:002013Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.23389994Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JSHepatology (Baltimore, Md.)Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013 Jul; 58(1):182-91.Hepatology2013-05-15T00:00:002013Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520.23410973Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang WCancer cellIntegrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99.Cancer Cell2013-02-11T00:00:002013Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.23555186Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu JNeoplasia (New York, N.Y.)Interleukin-1? promotes ovarian tumorigenesis through a p53/NF-?B-mediated inflammatory response in stromal fibroblasts. Neoplasia. 2013 Apr; 15(4):409-20.Neoplasia2013-04-01T00:00:002013Interleukin-1? promotes ovarian tumorigenesis through a p53/NF-?B-mediated inflammatory response in stromal fibroblasts.23557989Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, Tang H, Huang TH, Liu Y, Rusch DB, Nephew KPMethods (San Diego, Calif.)A new method for stranded whole transcriptome RNA-seq. Methods. 2013 Sep 15; 63(2):126-34.Methods2013-04-01T00:00:002013A new method for stranded whole transcriptome RNA-seq.23585472Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AKThe Journal of clinical investigationATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.J Clin Invest2013-04-15T00:00:002013ATP11B mediates platinum resistance in ovarian cancer.23887388Gharpure KM, Sood AKCell cycle (Georgetown, Tex.)Neighborhood matters: response to EZH2 methyltransferase inhibitors. Cell Cycle. 2013 Aug 01; 12(15):2345.Cell Cycle2013-07-16T00:00:002013Neighborhood matters: response to EZH2 methyltransferase inhibitors.23907406Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock RInvestigational new drugsMethylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200.Invest New Drugs2013-08-02T00:00:002013Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.23912484Melhem-Bertrandt A, Sood AKCancer biomarkers : section A of Disease markersAdrenergic signaling and cancer: deciphering the connections. Cancer Biomark. 2013; 13(3):131-2.Cancer Biomark2013-01-01T00:00:002013Adrenergic signaling and cancer: deciphering the connections.24018975Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AKNature communicationsTumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.Nat Commun2013-01-01T00:00:002013Tumour angiogenesis regulation by the miR-200 family.24096110Lutgendorf SK, Slavich GM, Degeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J, Mendez L, Collins K, Sood AKGynecologic oncologyNon-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. Gynecol Oncol. 2013 Dec; 131(3):667-73.Gynecol Oncol2013-10-03T00:00:002013Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.24097061Wan G, Hu X, Liu Y, Han C, Sood AK, Calin GA, Zhang X, Lu XThe EMBO journalA novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J. 2013 Oct 30; 32(21):2833-47.EMBO J2013-10-04T00:00:002013A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation.24183729Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AKGynecologic oncologyPlatelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan; 132(1):166-75.Gynecol Oncol2013-10-29T00:00:002013Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma.24231349Wang H, Heijnen CJ, van Velthoven CT, Willemen HL, Ishikawa Y, Zhang X, Sood AK, Vroon A, Eijkelkamp N, Kavelaars AThe Journal of clinical investigationBalancing GRK2 and EPAC1 levels prevents and relieves chronic pain. J Clin Invest. 2013 Dec; 123(12):5023-34.J Clin Invest2013-11-15T00:00:002013Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.24236104Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee PPloS oneCystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.PLoS One2013-11-13T00:00:002013Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.24480297Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala VJournal of clinical anesthesiaPerioperative beta-blocker use and survival in lung cancer patients. J Clin Anesth. 2014 Mar; 26(2):106-17.J Clin Anesth2014-01-28T00:00:002014Perioperative beta-blocker use and survival in lung cancer patients.24511017Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, Mills GB, Sood A, Lee JSAnticancer researchActivation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 2014 Feb; 34(2):811-817.Anticancer Res2014-02-01T00:00:002014Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.24556724Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AKCancer researchMonocyte subpopulations in angiogenesis. Cancer Res. 2014 Mar 01; 74(5):1287-93.Cancer Res2014-02-20T00:00:002014Monocyte subpopulations in angiogenesis.24674832Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AKGynecologic oncologyEstrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol. 2014 Jun; 133(3):473-9.Gynecol Oncol2014-03-25T00:00:002014Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.24931336Gizzatov A, Stigliano C, Ananta JS, Sethi R, Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi PCancer lettersGeometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett. 2014 Sep 28; 352(1):97-101.Cancer Lett2014-06-12T00:00:002014Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer.25023353Davis AN, Afshar-Kharghan V, Sood AKSeminars in oncologyPlatelet effects on ovarian cancer. Semin Oncol. 2014 Jun; 41(3):378-84.Semin Oncol2014-04-23T00:00:002014Platelet effects on ovarian cancer.25026212Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AKCancer cellHematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.Cancer Cell2014-07-14T00:00:002014Hematogenous metastasis of ovarian cancer: rethinking mode of spread.25043055Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YNaturemiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014 Aug 28; 512(7515):431-5.Nature2014-06-25T00:00:002014miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Authorship 2388691Authorship 2392131Authorship 2398021Authorship 2401093Authorship 2407241Authorship 2407802Authorship 2410301Authorship 2412633Authorship 241945Authorship 2425973Authorship 2430431Authorship 2439121Authorship 2444594Authorship 2447562Authorship 24503610Authorship 2450713Authorship 2458452Authorship 2465171Authorship 246728Authorship 2469565Authorship 2469708Authorship 2472401Authorship 2474988Authorship 2479102Authorship 24797319Authorship 24802712Authorship 2487712Authorship 2491152Authorship 24918110Authorship 24952912Authorship 2495512Authorship 2497312Authorship 2498009Authorship 24993114Authorship 2501453Authorship 25022911Authorship 25056110Authorship 2506643Authorship 2509896Authorship 25107114Authorship 25157114Authorship 2518461Authorship 25186311Authorship 2520534Authorship 25215120Authorship 2522942Authorship 2526033Authorship 2526706Authorship 25269712Authorship 2528702Authorship 2529332Authorship 25298811Authorship 2534642Authorship 2535929Authorship 25382711Authorship 2538974Authorship 2540224Authorship 2543087Authorship 25432113Authorship 25441313Authorship 2544215Authorship 2545086Authorship 2545601Authorship 25461538Authorship 25464016Authorship 25465319Authorship 2548272Authorship 2549058Authorship 2549893Authorship 2550057Authorship 2550304Authorship 2551053Authorship 2552731Authorship 2554422Authorship 2556315Authorship 2558439Authorship 2558615Authorship 2559507Authorship 2562791Authorship 25632616Authorship 2564662Authorship 2567878Authorship 2569498Authorship 2574956Authorship 25758011Authorship 2578077Authorship 2578862Authorship 2583323Authorship 25839814Authorship 2585613Authorship 25856419Authorship 2587972Authorship 25880312Authorship 2590656Authorship 2591008Authorship 2591098Authorship 25962613Authorship 26009312Authorship 2601406Authorship 26031417Authorship 26075219Authorship 2607653Authorship 26107618Authorship 2615808Authorship 261811227705695Sood AK, Gelder MS, Huang SW, Morgan LSGynecologic oncologyAnaphylaxis to carboplatin following multiple previous uncomplicated courses. Gynecol Oncol. 1995 Apr; 57(1):131-2.Gynecol Oncol1995-04-01T00:00:001995Anaphylaxis to carboplatin following multiple previous uncomplicated courses.7770263Sood AK, Yancey M, Richards DObstetrics and gynecologyPrediction of fetal macrosomia using humeral soft tissue thickness. Obstet Gynecol. 1995 Jun; 85(6):937-40.Obstet Gynecol1995-06-01T00:00:001995Prediction of fetal macrosomia using humeral soft tissue thickness.8957095Sood AK, Buller REOncogeneGenomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction. Oncogene. 1996 Dec 05; 13(11):2499-504.Oncogene1996-12-05T00:00:001996Genomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction.9264586Rasmussen CC, Sood AK, Sorosky JI, Anderson BGynecologic oncologyPosterior exenteration through groin incision in a patient with stage III vulvar carcinoma. Gynecol Oncol. 1997 Aug; 66(2):331-4.Gynecol Oncol1997-08-01T00:00:001997Posterior exenteration through groin incision in a patient with stage III vulvar carcinoma.9277659Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman MObstetrics and gynecologyValue of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997 Sep; 90(3):441-7.Obstet Gynecol1997-09-01T00:00:001997Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome.9576296Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LSCancerPrimary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer. 1998 May 01; 82(9):1731-7.Cancer1998-05-01T00:00:001998Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.9579425Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJAmerican journal of obstetrics and gynecologyField cancerization: why late "recurrent" ovarian cancer is not recurrent. Am J Obstet Gynecol. 1998 Apr; 178(4):641-9.Am J Obstet Gynecol1998-04-01T00:00:001998Field cancerization: why late "recurrent" ovarian cancer is not recurrent.10469755Boyd J, Narod SAJournal of the National Cancer InstituteRe: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst. 1999 Sep 01; 91(17):1507-9.J Natl Cancer Inst1999-09-01T00:00:001999Re: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.10684721Pertzborn S, Buekers TE, Sood AKGynecologic oncologyHematogenous skin metastases from cervical cancer at primary presentation. Gynecol Oncol. 2000 Mar; 76(3):416-7.Gynecol Oncol2000-03-01T00:00:002000Hematogenous skin metastases from cervical cancer at primary presentation.11064359Shahin MS, Hughes JH, Sood AK, Buller RECancerThe prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000 Nov 01; 89(9):2006-17.Cancer2000-11-01T00:00:002000The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.11389062Sood AK, Holmes R, Hendrix MJ, Buller RECancer researchApplication of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer. Cancer Res. 2001 Jun 01; 61(11):4371-4.Cancer Res2001-06-01T00:00:002001Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer.11733979Sood AK, Shahin MS, Sorosky JIGynecologic oncologyPaclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol. 2001 Dec; 83(3):599-600.Gynecol Oncol2001-12-01T00:00:002001Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.12100804Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller REObstetrics and gynecologyPreoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002 Jul; 100(1):59-64.Obstet Gynecol2002-07-01T00:00:002002Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.12885801Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JSJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol. 2003 Aug 01; 21(15):2856-9.J Clin Oncol2003-08-01T00:00:002003Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.14555525Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchStress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003 Oct 01; 9(12):4514-21.Clin Cancer Res2003-10-01T00:00:002003Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines.14601090Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RECancerMismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003 Nov 15; 98(10):2199-206.Cancer2003-11-15T00:00:002003Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.14758127Hsu Y, Sood AK, Sorosky JIAmerican journal of clinical oncologyDocetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol. 2004 Feb; 27(1):14-8.Am J Clin Oncol2004-02-01T00:00:002004Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.14766277Guven ES, Guven S, Ayhan AGynecologic oncologyComment on "Recurrent carcinoma in situ of a neovagina". Gynecol Oncol. 2004 Feb; 92(2):728; 728-9.Gynecol Oncol2004-02-01T00:00:002004Comment on "Recurrent carcinoma in situ of a neovagina".15118611Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJAmerican journal of obstetrics and gynecologyFunctional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004 Apr; 190(4):899-909.Am J Obstet Gynecol2004-04-01T00:00:002004Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.15466376Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJThe American journal of pathologyBiological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004 Oct; 165(4):1087-95.Am J Pathol2004-10-01T00:00:002004Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.15863143Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AKGynecologic oncologyMalignant mixed mullerian tumor (MMMT) of the cervix. Gynecol Oncol. 2005 May; 97(2):442-5.Gynecol Oncol2005-05-01T00:00:002005Malignant mixed mullerian tumor (MMMT) of the cervix.15970706Thaker PH, Yokoi K, Jennings NB, Li Y, Rebhun RB, Rousseau DL, Fan D, Sood AKCancer biology & therapyInhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal. Cancer Biol Ther. 2005 Jul; 4(7):753-8.Cancer Biol Ther2005-07-09T00:00:002005Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal.16192594Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DMJournal of clinical oncology : official journal of the American Society of Clinical OncologySocial support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005 Oct 01; 23(28):7105-13.J Clin Oncol2005-10-01T00:00:002005Social support, psychological distress, and natural killer cell activity in ovarian cancer.16288054Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJCancer researchExpression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005 Nov 15; 65(22):10602-12.Cancer Res2005-11-15T00:00:002005Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.16498446Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AKNature reviews. CancerThe influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006 03; 6(3):240-8.Nat Rev Cancer2006-03-01T00:00:002006The influence of bio-behavioural factors on tumour biology: pathways and mechanisms.16855388Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DMCancer biology & therapyThe BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.Cancer Biol Ther2006-09-28T00:00:002006The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.16969071Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN, Lu C, Gershenson DM, Simpson JL, Sood AKCancer biology & therapyCirculating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther. 2006 Oct; 5(10):1369-74.Cancer Biol Ther2006-10-26T00:00:002006Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.17040624Coleman RL, Sood AKCurrent oncology reportsHistorical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy. Curr Oncol Rep. 2006 Nov; 8(6):455-64.Curr Oncol Rep2006-11-01T00:00:002006Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy.17077358Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AKJournal of the National Cancer InstituteEfficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70.J Natl Cancer Inst2006-11-01T00:00:002006Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.17079456Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser RCancer researchNorepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006 Nov 01; 66(21):10357-64.Cancer Res2006-11-01T00:00:002006Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells.17210709Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AKCancer researchMetronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007 Jan 01; 67(1):281-8.Cancer Res2007-01-01T00:00:002007Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.17308118Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AKCancer researchGene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15; 67(4):1757-68.Cancer Res2007-02-15T00:00:002007Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.17329515Milam MR, Sood AK, King S, Bassett RL, Lu KH, Slomovitz BM, Coleman RL, Ramirez PTObstetrics and gynecologySupracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2007 Mar; 109(3):641-6.Obstet Gynecol2007-03-01T00:00:002007Supracervical hysterectomy in patients with advanced epithelial ovarian cancer.17403394Spannuth WA, Thaker PH, Sood AKAmerican journal of obstetrics and gynecologyConcomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. Am J Obstet Gynecol. 2007 Apr; 196(4):e6-9.Am J Obstet Gynecol2007-04-01T00:00:002007Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.17634535Landen CN, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchOverexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res. 2007 Jul 15; 13(14):4098-104.Clin Cancer Res2007-07-15T00:00:002007Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.18057525Merritt WM, Sood AKDisease markersMarkers of angiogenesis in ovarian cancer. Dis Markers. 2007; 23(5-6):419-31.Dis Markers2007-01-01T00:00:002007Markers of angiogenesis in ovarian cancer.18094433Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchClinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95.Clin Cancer Res2007-12-15T00:00:002007Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.18195328Landen CN, Birrer MJ, Sood AKJournal of clinical oncology : official journal of the American Society of Clinical OncologyEarly events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20; 26(6):995-1005.J Clin Oncol2008-01-14T00:00:002008Early events in the pathogenesis of epithelial ovarian cancer.18336345Sanguino A, Lopez-Berestein G, Sood AKMini reviews in medicinal chemistryStrategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 2008 Mar; 8(3):248-55.Mini Rev Med Chem2008-03-01T00:00:002008Strategies for in vivo siRNA delivery in cancer.18395047Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AKAmerican journal of obstetrics and gynecologyImpact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10.Am J Obstet Gynecol2008-04-01T00:00:002008Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.18443431Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AKCancer biology & therapyEphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008 Jul; 7(7):1098-103.Cancer Biol Ther2008-04-19T00:00:002008EphA2 overexpression promotes ovarian cancer growth.18550328Lutgendorf SK, DeGeest K, Sung CY, Arevalo JM, Penedo F, Lucci J, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SWBrain, behavior, and immunityDepression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun. 2009 Feb; 23(2):176-83.Brain Behav Immun2008-06-11T00:00:002008Depression, social support, and beta-adrenergic transcription control in human ovarian cancer.18595162Sood AK, Birrer MJGynecologic oncologyHighlights from the 2008 Annual Meeting of the American Association for Cancer Research. Gynecol Oncol. 2008 Jul; 110(1):5-6.Gynecol Oncol2008-07-01T00:00:002008Highlights from the 2008 Annual Meeting of the American Association for Cancer Research.18644993Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ESMolecular cancer therapeuticsTargeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther. 2008 Jul; 7(7):1807-16.Mol Cancer Ther2008-07-01T00:00:002008Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.18765535Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.Clin Cancer Res2008-09-01T00:00:002008Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.18953435Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AKNeoplasia (New York, N.Y.)Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia. 2008 Nov; 10(11):1259-67.Neoplasia2008-11-01T00:00:002008Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.19156916Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SKCancerGlucose as a prognostic factor in ovarian carcinoma. Cancer. 2009 Mar 01; 115(5):1021-7.Cancer2009-03-01T00:00:002009Glucose as a prognostic factor in ovarian carcinoma.19162310Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DMGynecologic oncologyPatterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol. 2009 Apr; 113(1):86-90.Gynecol Oncol2009-01-21T00:00:002009Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?19361839Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJGynecologic oncologyRecurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.Gynecol Oncol2009-04-10T00:00:002009Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.19383821Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEstrous cycle modulates ovarian carcinoma growth. Clin Cancer Res. 2009 May 01; 15(9):2971-8.Clin Cancer Res2009-04-21T00:00:002009Estrous cycle modulates ovarian carcinoma growth.19495686Mangala LS, Han HD, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.Methods Mol Biol2009-01-01T00:00:002009Liposomal siRNA for ovarian cancer.19519199Moroney JW, Sood AK, Coleman RLFuture oncology (London, England)Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun; 5(5):591-600.Future Oncol2009-06-01T00:00:002009Aflibercept in epithelial ovarian carcinoma.19780895Cai YQ, Chen SR, Han HD, Sood AK, Lopez-Berestein G, Pan HLJournal of neurochemistryRole of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem. 2009 Nov; 111(4):1000-10.J Neurochem2009-09-23T00:00:002009Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats.19805003Shahzad MM, Lopez-Berestein G, Sood AKDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyNovel strategies for reversing platinum resistance. Drug Resist Updat. 2009 Dec; 12(6):148-52.Drug Resist Updat2009-10-04T00:00:002009Novel strategies for reversing platinum resistance.19829059Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AKCancer biology & therapyCombined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72.Cancer Biol Ther2009-12-19T00:00:002009Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.19840886Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AKGynecologic oncologyClinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 2010 Jan; 116(1):61-5.Gynecol Oncol2009-10-17T00:00:002009Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.20059643Ozpolat B, Sood AK, Lopez-Berestein GJournal of internal medicineNanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53.J Intern Med2010-01-01T00:00:002010Nanomedicine based approaches for the delivery of siRNA in cancer.20092424Spannuth WA, Sood AK, Coleman RLExpert opinion on biological therapyFarletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010 Mar; 10(3):431-7.Expert Opin Biol Ther2010-03-01T00:00:002010Farletuzumab in epithelial ovarian carcinoma.20176930Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TEProceedings of the National Academy of Sciences of the United States of AmericaComputational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A. 2010 Mar 23; 107(12):5681-6.Proc Natl Acad Sci U S A2010-02-22T00:00:002010Computational identification of gene-social environment interaction at the human IL6 locus.20389021Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SKThe Journal of clinical investigationAdrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May; 120(5):1515-23.J Clin Invest2010-04-12T00:00:002010Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.20644093Lutgendorf SK, Sood AK, Antoni MHJournal of clinical oncology : official journal of the American Society of Clinical OncologyHost factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol. 2010 Sep 10; 28(26):4094-9.J Clin Oncol2010-07-19T00:00:002010Host factors and cancer progression: biobehavioral signaling pathways and interventions.20708159Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AKCancer cellRegulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.Cancer Cell2010-08-09T00:00:002010Regulation of tumor angiogenesis by EZH2.20815774Matsuo K, Lin YG, Roman LD, Sood AKExpert opinion on investigational drugsOvercoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010 Nov; 19(11):1339-54.Expert Opin Investig Drugs2010-09-06T00:00:002010Overcoming platinum resistance in ovarian carcinoma.20823155Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SWCancer researchThe sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010 Sep 15; 70(18):7042-52.Cancer Res2010-09-07T00:00:002010The sympathetic nervous system induces a metastatic switch in primary breast cancer.20826776Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AKThe Journal of biological chemistryStress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov 12; 285(46):35462-70.J Biol Chem2010-09-08T00:00:002010Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.20921883Matsuo K, Eno ML, Ahn EH, Shahzad MM, Im DD, Rosenshein NB, Sood AKAmerican journal of clinical oncologyMultidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol. 2011 Oct; 34(5):488-93.Am J Clin Oncol2011-10-01T00:00:002011Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.20948320Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AKCancer biology & therapyClinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14.Cancer Biol Ther2010-12-15T00:00:002010Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.20955777Lutgendorf SK, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SWBrain, behavior, and immunitySocial isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun. 2011 Feb; 25(2):250-5.Brain Behav Immun2010-10-16T00:00:002010Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients.21094927Costanzo ES, Sood AK, Lutgendorf SKImmunology and allergy clinics of North AmericaBiobehavioral influences on cancer progression. Immunol Allergy Clin North Am. 2011 Feb; 31(1):109-32.Immunol Allergy Clin North Am2011-02-01T00:00:002011Biobehavioral influences on cancer progression.21142861Moreno-Smith M, Lutgendorf SK, Sood AKFuture oncology (London, England)Impact of stress on cancer metastasis. Future Oncol. 2010 Dec; 6(12):1863-81.Future Oncol2010-12-01T00:00:002010Impact of stress on cancer metastasis.21160526Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AKNature reviews. CancerRNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67.Nat Rev Cancer2010-12-16T00:00:002010RNA interference in the clinic: challenges and future directions.21182930Lamkin DM, Lutgendorf SK, Lubaroff D, Sood AK, Beltz TG, Johnson AKBrain, behavior, and immunityCancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav Immun. 2011 Mar; 25(3):555-64.Brain Behav Immun2010-12-21T00:00:002010Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing.21300758Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchFunctional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21.Clin Cancer Res2011-02-07T00:00:002011Functional roles of Src and Fgr in ovarian carcinoma.21320669Sood AK, Wilson MT, Herzog TJGynecologic oncologySupporting gynecologic cancer research: the last 20 years and beyond. Gynecol Oncol. 2011 Mar; 120(3):319-20.Gynecol Oncol2011-03-01T00:00:002011Supporting gynecologic cancer research: the last 20 years and beyond.21358280Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AKCancer biology & therapyChitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45.Cancer Biol Ther2011-05-01T00:00:002011Chitosan hydrogel for localized gene silencing.21445297Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya RPloS oneEnhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.PLoS One2011-03-21T00:00:002011Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer.21464029Sood AK, Lutgendorf SKCancer prevention research (Philadelphia, Pa.)Stress influences on anoikis. Cancer Prev Res (Phila). 2011 Apr; 4(4):481-5.Cancer Prev Res (Phila)2011-04-01T00:00:002011Stress influences on anoikis.21472713Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RCCancerPhase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.Cancer2010-11-08T00:00:002010Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.21512144Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer ResearchSilencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3716-26.Clin Cancer Res2011-04-21T00:00:002011Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.21532880Schauer IG, Sood AK, Mok S, Liu JNeoplasia (New York, N.Y.)Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia. 2011 May; 13(5):393-405.Neoplasia2011-05-01T00:00:002011Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.21632501Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AMJournal of clinical oncology : official journal of the American Society of Clinical OncologyBeta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2645-52.J Clin Oncol2011-05-31T00:00:002011Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.21647195Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GANature reviews. Clinical oncologyMicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011 Jun 07; 8(8):467-77.Nat Rev Clin Oncol2011-06-07T00:00:002011MicroRNAs in body fluids--the mix of hormones and biomarkers.21990299Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang WJAMAAssociation of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011 Oct 12; 306(14):1557-65.JAMA2011-10-12T00:00:002011Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.22045356Huang J, Hu W, Sood AKCancer biomarkers : section A of Disease markersPrognostic biomarkers in ovarian cancer. Cancer Biomark. 2010-2011; 8(4-5):231-51.Cancer Biomark2010-01-01T00:00:002010Prognostic biomarkers in ovarian cancer.22068913Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MMProceedings of the National Academy of Sciences of the United States of AmericaRedefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18708-13.Proc Natl Acad Sci U S A2011-11-08T00:00:002011Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.22436627Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi RHuman pathologyClinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol. 2012 Oct; 43(10):1638-44.Hum Pathol2012-03-19T00:00:002012Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.22487539Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GBGynecologic oncologyPerifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53.Gynecol Oncol2012-04-06T00:00:002012Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.22492981Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MMClinical cancer research : an official journal of the American Association for Cancer ResearchMultidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res. 2012 Jun 01; 18(11):3197-206.Clin Cancer Res2012-04-05T00:00:002012Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.22710075Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AKGynecologic oncologyPhase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4.Gynecol Oncol2012-06-16T00:00:002012Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.22854961Zhou HY, Chen SR, Byun HS, Chen H, Li L, Han HD, Lopez-Berestein G, Sood AK, Pan HLThe Journal of biological chemistryN-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J Biol Chem. 2012 Sep 28; 287(40):33853-64.J Biol Chem2012-08-01T00:00:002012N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain.22865457You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK, Li CCancer researchEffective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 2012 Sep 15; 72(18):4777-86.Cancer Res2012-08-03T00:00:002012Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors.23057551Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang WPharmacogenomicsDiffering clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics. 2012 Oct; 13(13):1523-35.Pharmacogenomics2012-10-01T00:00:002012Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.23190436Miyake TM, Sood AK, Coleman RLExpert opinion on biological therapyContemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther. 2013 Feb; 13(2):283-94.Expert Opin Biol Ther2012-11-29T00:00:002012Contemporary use of bevacizumab in ovarian cancer.23200915Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AKGynecologic oncologyEpigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.Gynecol Oncol2012-11-28T00:00:002012Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.23381004Coleman RL, Monk BJ, Sood AK, Herzog TJNature reviews. Clinical oncologyLatest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr; 10(4):211-24.Nat Rev Clin Oncol2013-02-05T00:00:002013Latest research and treatment of advanced-stage epithelial ovarian cancer.23386691Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer ResearchEnhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013 Apr 01; 19(7):1806-15.Clin Cancer Res2013-02-05T00:00:002013Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.23797955Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SKCancerSleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer. 2013 Sep 01; 119(17):3234-41.Cancer2013-06-24T00:00:002013Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.23798432Jin Y, Qu S, Tesikova M, Wang L, Kristian A, M?landsmo GM, Kong H, Zhang T, Jer?nimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu FProceedings of the National Academy of Sciences of the United States of AmericaMolecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):E2572-81.Proc Natl Acad Sci U S A2013-06-24T00:00:002013Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.23800698Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DMGynecologic oncologyPoor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 2013 Sep; 130(3):565-9.Gynecol Oncol2013-06-22T00:00:002013Poor survival with wild-type TP53 ovarian cancer?23871637Masiero M, Sim?es FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FMCancer cellA core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.Cancer Cell2013-07-18T00:00:002013A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.24062525Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AKJournal of the National Cancer InstituteRole of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95.J Natl Cancer Inst2013-09-23T00:00:002013Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.24079419Aslan B, Ozpolat B, Sood AK, Lopez-Berestein GJournal of drug targetingNanotechnology in cancer therapy. J Drug Target. 2013 Dec; 21(10):904-13.J Drug Target2013-09-30T00:00:002013Nanotechnology in cancer therapy.24243015Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MACellSystematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013 Oct 24; 155(3):552-66.Cell2013-10-24T00:00:002013Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.24613353Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan VCell reportsAutocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095.Cell Rep2014-03-06T00:00:002014Autocrine effects of tumor-derived complement.24769442Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TWCancer researchAPI5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res. 2014 Jul 01; 74(13):3556-66.Cancer Res2014-04-25T00:00:002014API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.Authorship 2640392Authorship 2641651Authorship 2645931Authorship 2651701Authorship 2654653Authorship 2660681Authorship 2662585Authorship 2671951Authorship 2672305Authorship 26725614Authorship 26774510Authorship 26808311Authorship 2681157Authorship 26821817Authorship 26846810Authorship 26877215Authorship 26881422Authorship 26900812Authorship 2695714Authorship 26983118Authorship 26998421Authorship 27002520Authorship 2703325Authorship 2704736Authorship 2706653Authorship 2711117Authorship 2711637Authorship 27162527Authorship 2717174Authorship 27174110Authorship 27185929253509Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson BCancer gene therapyThe influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther. 1997 Jul-Aug; 4(4):239-45.Cancer Gene Ther1997-07-01T00:00:001997The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis.9629575Sood AK, Sorosky JIObstetrics and gynecology clinics of North AmericaInvasive cervical cancer complicating pregnancy. How to manage the dilemma. Obstet Gynecol Clin North Am. 1998 Jun; 25(2):343-52.Obstet Gynecol Clin North Am1998-06-01T00:00:001998Invasive cervical cancer complicating pregnancy. How to manage the dilemma.9699774Sood AK, Buller REObstetrics and gynecologyDrug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol. 1998 Aug; 92(2):312-9.Obstet Gynecol1998-08-01T00:00:001998Drug resistance in ovarian cancer: from the laboratory to the clinic.10499623Sood AK, Sorosky JI, Dolan M, Anderson B, Buller REClinical cancer research : an official journal of the American Association for Cancer ResearchDistant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res. 1999 Sep; 5(9):2485-90.Clin Cancer Res1999-09-01T00:00:001999Distant metastases in ovarian cancer: association with p53 mutations.12079305Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller REGynecologic oncologyOvarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol. 2002 Jul; 86(1):85-90.Gynecol Oncol2002-07-01T00:00:002002Ovarian cancer p53 mutation is associated with tumor microvessel density.15477760Landen CN, Klingelhutz A, Coffin JE, Sorosky JI, Sood AKCancer biology & therapyGenomic instability is associated with lack of telomerase activation in ovarian cancer. Cancer Biol Ther. 2004 Dec; 3(12):1250-3.Cancer Biol Ther2004-12-14T00:00:002004Genomic instability is associated with lack of telomerase activation in ovarian cancer.15738017Sood AK, Cooper BC, Sorosky JI, Ramirez PT, Levenback CObstetrics and gynecologyNovel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation. Obstet Gynecol. 2005 Mar; 105(3):514-8.Obstet Gynecol2005-03-01T00:00:002005Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation.15907981Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DMGynecologic oncologyFifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol. 2005 Jun; 97(3):916-23.Gynecol Oncol2005-06-01T00:00:002005Fifth International Conference on Ovarian Cancer: challenges and opportunities.16203789Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RBClinical cancer research : an official journal of the American Association for Cancer ResearchVascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6966-71.Clin Cancer Res2005-10-01T00:00:002005Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.17106249Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AKCancer biology & therapyIntraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.Cancer Biol Ther2006-12-30T00:00:002006Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.18413840Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta KClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2476-83.Clin Cancer Res2008-04-15T00:00:002008Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.18765538Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, Pollock RE, Lev DClinical cancer research : an official journal of the American Association for Cancer ResearchCombined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res. 2008 Sep 01; 14(17):5466-75.Clin Cancer Res2008-09-01T00:00:002008Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.18980978Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA, Cole SW, Lubaroff DM, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchBiobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res. 2008 Nov 01; 14(21):6839-46.Clin Cancer Res2008-11-01T00:00:002008Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma.19058181Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AKInternational journal of cancerFunctional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53.Int J Cancer2009-03-01T00:00:002009Functional significance of VEGFR-2 on ovarian cancer cells.19092150Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AKThe New England journal of medicineDicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.N Engl J Med2008-12-18T00:00:002008Dicer, Drosha, and outcomes in patients with ovarian cancer.19351748Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchSurgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009 Apr 15; 15(8):2695-702.Clin Cancer Res2009-04-07T00:00:002009Surgical stress promotes tumor growth in ovarian carcinoma.19396818Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AKCancerEphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92.Cancer2009-06-15T00:00:002009EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.20166213Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AKCancerPlasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010 Apr 15; 116(8):1918-25.Cancer2010-04-15T00:00:002010Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.20665499Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JKCancerCombination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9.Cancer2010-11-01T00:00:002010Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.20708153Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RCCancer cellSIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010 Aug 09; 18(2):109-21.Cancer Cell2010-08-09T00:00:002010SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.21795478Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AKCancer researchBiological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9.Cancer Res2011-07-27T00:00:002011Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.22180853Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AKCancer discoveryA novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011 Dec; 1(7):580-6.Cancer Discov2011-11-03T00:00:002011A novel platform for detection of CK+ and CK- CTCs.22187436Li L, Cao XH, Chen SR, Han HD, Lopez-Berestein G, Sood AK, Pan HLThe Journal of biological chemistryUp-regulation of Cav?3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain. J Biol Chem. 2012 Feb 17; 287(8):6002-13.J Biol Chem2011-12-20T00:00:002011Up-regulation of Cav?3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain.22390757Thanapprapasr D, Hu W, Sood AK, Coleman RLCurrent pharmaceutical designMoving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9.Curr Pharm Des2012-01-01T00:00:002012Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.22543257Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Penedo F, Lubaroff DM, Sood AK, Lutgendorf SKBrain, behavior, and immunitySleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav Immun. 2012 Oct; 26(7):1037-44.Brain Behav Immun2012-04-21T00:00:002012Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.22590536Liu Y, Sun Y, Broaddus R, Liu J, Sood AK, Shmulevich I, Zhang WPloS oneIntegrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One. 2012; 7(5):e36383.PLoS One2012-05-08T00:00:002012Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma.22911754Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat BPloS oneTargeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171.PLoS One2012-07-20T00:00:002012Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.23042265Kloc M, Tejpal N, Sidhu J, Ganachari M, Flores-Villanueva P, Jennings NB, Sood AK, Kubiak JZ, Ghobrial RMFolia histochemica et cytobiologicaInverse relationship between TCTP/RhoA and p53 /cyclin A/actin expression in ovarian cancer cells. Folia Histochem Cytobiol. 2012 Oct 08; 50(3):358-67.Folia Histochem Cytobiol2012-10-08T00:00:002012Inverse relationship between TCTP/RhoA and p53 /cyclin A/actin expression in ovarian cancer cells.23348736Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AKThe Journal of clinical investigationWhy stress is BAD for cancer patients. J Clin Invest. 2013 Feb; 123(2):558-60.J Clin Invest2013-01-25T00:00:002013Why stress is BAD for cancer patients.24384374Ozpolat B, Sood AK, Lopez-Berestein GAdvanced drug delivery reviewsLiposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6.Adv Drug Deliv Rev2013-12-30T00:00:002013Liposomal siRNA nanocarriers for cancer therapy.24743243Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AKCancer researchNotch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.Cancer Res2014-04-17T00:00:002014Notch3 pathway alterations in ovarian cancer.Authorship 2725733Authorship 2726742Authorship 2728161Authorship 2731205Authorship 27340316Authorship 2734462Authorship 2735191Authorship 2735449Authorship 27397418Authorship 2741048Authorship 27421015Authorship 27422714Authorship 27426419Authorship 2742752Authorship 2743507Authorship 27466515Authorship 2752815Authorship 27529722Authorship 2766842Authorship 2771771Authorship 2772541Authorship 2773263Authorship 2776483Authorship 2777073Authorship 27783629500496Signore CC, Sood AK, Richards DSAmerican journal of obstetrics and gynecologySecond-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome. Am J Obstet Gynecol. 1998 Feb; 178(2):336-40.Am J Obstet Gynecol1998-02-01T00:00:001998Second-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome.11779615Lowe MP, Bender D, Sood AK, Davis W, Syrop CH, Sorosky JIFertility and sterilityTwo successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril. 2002 Jan; 77(1):188-9.Fertil Steril2002-01-01T00:00:002002Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction.12083994Eichholz AC, Mahavni V, Sood AKExpert opinion on pharmacotherapyAllopathic and complementary alternatives to hormone replacement therapy. Expert Opin Pharmacother. 2002 Jul; 3(7):949-55.Expert Opin Pharmacother2002-07-01T00:00:002002Allopathic and complementary alternatives to hormone replacement therapy.12496479Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz ACancer biology & therapyp53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther. 2002 Sep-Oct; 1(5):511-7.Cancer Biol Ther2002-09-01T00:00:002002p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.12642690Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJCancer biology & therapyThe clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther. 2002 Nov-Dec; 1(6):661-4.Cancer Biol Ther2002-11-01T00:00:002002The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy.14675678Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JIGynecologic oncologyImplementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol. 2003 Dec; 91(3):569-72.Gynecol Oncol2003-12-01T00:00:002003Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia.15957979Sood AK, Coleman RL, Wolf JK, Gershenson DMExpert opinion on pharmacotherapySelected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother. 2005 Jun; 6(7):1269-75.Expert Opin Pharmacother2005-06-01T00:00:002005Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.16300469Landen CN, Kinch MS, Sood AKExpert opinion on therapeutic targetsEphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets. 2005 Dec; 9(6):1179-87.Expert Opin Ther Targets2005-12-01T00:00:002005EphA2 as a target for ovarian cancer therapy.16880307Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DCObstetrics and gynecologyClinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.Obstet Gynecol2006-08-01T00:00:002006Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.17108216Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZAnnals of the New York Academy of SciencesQuantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci. 2006 Sep; 1075:230-4.Ann N Y Acad Sci2006-09-01T00:00:002006Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.17666626Sood AKObstetrics and gynecologyCancer in surgical scar: insights and clinical challenges. Obstet Gynecol. 2007 Aug; 110(2 Pt 2):453-4.Obstet Gynecol2007-08-01T00:00:002007Cancer in surgical scar: insights and clinical challenges.18201896Thaker PH, Sood AKSeminars in cancer biologyNeuroendocrine influences on cancer biology. Semin Cancer Biol. 2008 Jun; 18(3):164-70.Semin Cancer Biol2007-12-08T00:00:002007Neuroendocrine influences on cancer biology.18276105Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DMBrain, behavior, and immunityDepressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun. 2008 Aug; 22(6):890-900.Brain Behav Immun2008-02-13T00:00:002008Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients.19524286Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown JGynecologic oncologyAnti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009 Sep; 114(3):431-6.Gynecol Oncol2009-06-13T00:00:002009Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.19641174Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AKJournal of the National Cancer InstituteEphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.J Natl Cancer Inst2009-07-29T00:00:002009EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.19738426Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AKCancer biology & therapyAnti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603.Cancer Biol Ther2009-08-13T00:00:002009Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.20538762Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTargeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug 01; 16(15):3910-22.Clin Cancer Res2010-06-10T00:00:002010Targeted gene silencing using RGD-labeled chitosan nanoparticles.21531818Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchDopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun 01; 17(11):3649-59.Clin Cancer Res2011-04-29T00:00:002011Dopamine blocks stress-mediated ovarian carcinoma growth.21754983Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJPloS oneIdentification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121.PLoS One2011-07-06T00:00:002011Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.21780419Lee JS, Rodr?guez-Luccioni HL, M?ndez J, Sood AK, Lpez-Berestein G, Rinaldi C, Torres-Lugo MJournal of nanoscience and nanotechnologyHyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol. 2011 May; 11(5):4153-7.J Nanosci Nanotechnol2011-05-01T00:00:002011Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum.21992853Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AKThe Lancet. OncologyPhase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17.Lancet Oncol2011-10-10T00:00:002011Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.22072418Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DMCancerReclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.Cancer2011-11-09T00:00:002011Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.22387451Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DMGynecologic oncologyPhase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.Gynecol Oncol2012-02-28T00:00:002012Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.23919278Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AKExpert opinion on investigational drugs?-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs. 2013 Nov; 22(11):1359-63.Expert Opin Investig Drugs2013-08-07T00:00:002013?-blockers: a new role in cancer chemotherapy?24002999Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GACancer discoveryTherapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15.Cancer Discov2013-09-03T00:00:002013Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.Authorship 278701977Authorship 27873115Authorship 27895529Authorship 27962517Authorship 2799631425901683Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu XNatureTP53 loss creates therapeutic vulnerability in?colorectal cancer. Nature. 2015 Apr 30; 520(7549):697-701.Nature2015-04-22T00:00:002015TP53 loss creates therapeutic vulnerability in?colorectal cancer.26578771Wang R, Stone RL, Kaelber JT, Rochat RH, Nick AM, Vijayan KV, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK, Chiu WProceedings of the National Academy of Sciences of the United States of AmericaElectron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):14266-71.Proc Natl Acad Sci U S A2015-11-02T00:00:002015Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer.26799652Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Alg?l H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, B?nhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolom? A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, B?dard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, B?nard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, B?ckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouch? M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, B?tikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ce?a V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et alAutophagyGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.Autophagy2016-01-01T00:00:002016Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).Authorship 2817553Authorship 2840308Authorship 2846633Authorship 2861205Authorship 2862188Authorship 2862742Authorship 2867353Authorship 28677911Authorship 28683910Authorship 28703521Authorship 2877557Authorship 2883773Authorship 28874738Authorship 28877220Authorship 2890034Authorship 2890666Authorship 28929517Authorship 28934016Authorship 2895205Authorship 28956425Authorship 28969816Authorship 28970217Authorship 28994315Authorship 29014114Authorship 2903194Authorship 2905291Authorship 2905325Authorship 2910324Authorship 2912404Authorship 2912415Authorship 29131811Authorship 2915958Authorship 29162522Authorship 29190417Authorship 2919864Authorship 29206316Authorship 29214111Authorship 29217321Authorship 2923073Authorship 29235929Authorship 29258516Authorship 2925935Authorship 29265917Authorship 2931528Authorship 2932235Authorship 2933394Authorship 2933596Authorship 2935279Authorship 29366217Authorship 2943214Authorship 29461716Authorship 2949994Authorship 29512912Authorship 29523810Authorship 29526020Authorship 2953484Authorship 2957515Authorship 29577212Authorship 29624913Authorship 29653919Authorship 29684522Authorship 2975145Authorship 29753812Authorship 29814820Authorship 2984366Authorship 2992553Authorship 29935426Authorship 29945645Authorship 29966613Authorship 30037812Authorship 3008636Authorship 30117537Authorship 30160212Authorship 30177726Authorship 3018733Authorship 3018765Authorship 30209310Authorship 3023845Authorship 30239818Authorship 3033467Authorship 3036997Authorship 3043544Authorship 30465514Authorship 3047922Authorship 3048709Authorship 30489219Authorship 30552329Authorship 30559512Authorship 30560110Authorship 3134872Authorship 3144714Authorship 314636222812534Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RKBreast cancer research : BCRTargeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012 Jul 19; 14(4):R108.Breast Cancer Res2012-07-19T00:00:002012Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.15022840Godbole S, Sood A, Sharma M, Nagar PK, Ahuja PSJournal of plant physiologyStarch deposition and amylase accumulation during somatic embryogenesis in bamboo (Dendrocalamus hamiltonii). J Plant Physiol. 2004 Feb; 161(2):245-8.J Plant Physiol2004-02-01T00:00:002004Starch deposition and amylase accumulation during somatic embryogenesis in bamboo (Dendrocalamus hamiltonii).16169183Pati PK, Rath SP, Sharma M, Sood A, Ahuja PSBiotechnology advancesIn vitro propagation of rose--a review. Biotechnol Adv. 2006 Jan-Feb; 24(1):94-114.Biotechnol Adv2005-10-05T00:00:002005In vitro propagation of rose--a review.16369766Thakur R, Sood A, Nagar PK, Pandey S, Sobti RC, Ahuja PSPlant cell reportsRegulation of growth of Lilium plantlets in liquid medium by application of paclobutrazol or ancymidol, for its amenability in a bioreactor system: growth parameters. Plant Cell Rep. 2006 May; 25(5):382-91.Plant Cell Rep2005-12-20T00:00:002005Regulation of growth of Lilium plantlets in liquid medium by application of paclobutrazol or ancymidol, for its amenability in a bioreactor system: growth parameters.17728142Sharma B, Joseph A, Sood ABiologicals : journal of the International Association of Biological StandardizationA simple and rapid method for quantifying 2-phenoxyethanol (2-PE) in Diphtheria, Tetanus and w-Pertussis (DTwP) vaccine. Biologicals. 2008 Jan; 36(1):61-3.Biologicals2007-08-28T00:00:002007A simple and rapid method for quantifying 2-phenoxyethanol (2-PE) in Diphtheria, Tetanus and w-Pertussis (DTwP) vaccine.20704834McDonald PG, Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, Stefanek M, Sood AKDiscovery medicineA biobehavioral perspective of tumor biology. Discov Med. 2005 Dec; 5(30):520-6.Discov Med2005-12-01T00:00:002005A biobehavioral perspective of tumor biology.21485800Yadav SC, Yadav SK, Sood A, Sharma M, Singh BJournal of biomedical nanotechnologyDevelopment of antidiabetic nanomedicine from stevioside. J Biomed Nanotechnol. 2011 Feb; 7(1):54-5.J Biomed Nanotechnol2011-02-01T00:00:002011Development of antidiabetic nanomedicine from stevioside.22701279Nadha HK, Salwan R, Kasana RC, Anand M, Sood APharmacognosy magazineIdentification and elimination of bacterial contamination during in vitro propagation of Guadua angustifolia Kunth. Pharmacogn Mag. 2012 Apr; 8(30):93-7.Pharmacogn Mag2012-04-01T00:00:002012Identification and elimination of bacterial contamination during in vitro propagation of Guadua angustifolia Kunth.23022553Barwal I, Sood A, Sharma M, Singh B, Yadav SCColloids and surfaces. B, BiointerfacesDevelopment of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine. Colloids Surf B Biointerfaces. 2013 Jan 01; 101:510-6.Colloids Surf B Biointerfaces2012-07-17T00:00:002012Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine.23342265Matsuo K, Sheridan TB, Yoshino K, Miyake T, Hew KE, Im DD, Rosenshein NB, Mabuchi S, Enomoto T, Kimura T, Sood AK, Roman LDCancer medicineSignificance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med. 2012 Oct; 1(2):156-64.Cancer Med2012-09-14T00:00:002012Significance of lymphovascular space invasion in epithelial ovarian cancer.23441484Brar J, Anand M, Sood AIndian journal of experimental biologyIn vitro seed germination of economically important edible bamboo Dendrocalamus membranaceus Munro. Indian J Exp Biol. 2013 Jan; 51(1):88-96.Indian J Exp Biol2013-01-01T00:00:002013In vitro seed germination of economically important edible bamboo Dendrocalamus membranaceus Munro.23519775Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AKFrontiers in oncologyEnhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2013; 3:58.Front Oncol2013-03-20T00:00:002013Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.23633922Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AKNeoplasia (New York, N.Y.)Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia. 2013 May; 15(5):502-10.Neoplasia2013-05-01T00:00:002013Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.24022053Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat BMolecular therapy. Nucleic acidsTherapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids. 2013 Sep 10; 2:e121.Mol Ther Nucleic Acids2013-09-10T00:00:002013Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer.24443972Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BLJournal of liposome researchDelivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res. 2014 Sep; 24(3):182-90.J Liposome Res2014-01-20T00:00:002014Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue.24598126Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang WJournal of hematology & oncologyPost-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J Hematol Oncol. 2014 Mar 05; 7:19.J Hematol Oncol2014-03-05T00:00:002014Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions.24619206Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AKNature communications2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.Nat Commun2014-03-12T00:00:0020142'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.24634380Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchBiologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50.Clin Cancer Res2014-03-14T00:00:002014Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer.24677166Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang WOncology reportsMiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep. 2014 May; 31(5):2021-8.Oncol Rep2014-03-21T00:00:002014MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.24696047Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KVCancer metastasis reviewsPlatelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014 Mar; 33(1):231-69.Cancer Metastasis Rev2014-03-01T00:00:002014Platelets and cancer: a casual or causal relationship: revisited.24703838Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AKCell reportsAntagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.Cell Rep2014-04-03T00:00:002014Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.24755199Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AKMolecular cancer therapeuticsMetronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.Mol Cancer Ther2014-04-22T00:00:002014Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.24755674Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AKCancer biology & therapyFocal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther. 2014 Jul; 15(7):919-29.Cancer Biol Ther2014-04-23T00:00:002014Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.24756370Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8.Clin Cancer Res2014-04-22T00:00:002014Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.24785846Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ikeda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, Sood AKObstetrics and gynecologyEffect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. Obstet Gynecol. 2014 May; 123(5):957-965.Obstet Gynecol2014-05-01T00:00:002014Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer.24841852Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AKCancer biology & therapyClodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther. 2014 Aug; 15(8):1061-7.Cancer Biol Ther2014-05-19T00:00:002014Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.24920658Wu SY, Lopez-Berestein G, Calin GA, Sood AKScience translational medicineRNAi therapies: drugging the undruggable. Sci Transl Med. 2014 Jun 11; 6(240):240ps7.Sci Transl Med2014-06-11T00:00:002014RNAi therapies: drugging the undruggable.24974076Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick JMolecular oncologyBRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014 Dec; 8(8):1429-40.Mol Oncol2014-06-06T00:00:002014BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.25059044Sood A, Nadha HK, Sood S, Walia S, Parkash OIndian journal of experimental biologyLarge scale propagation of an exotic edible bamboo, Phyllostachys pubescens Mazel ex H. De Lehale (Moso Bamboo) using seeds. Indian J Exp Biol. 2014 Jul; 52(7):755-8.Indian J Exp Biol2014-07-01T00:00:002014Large scale propagation of an exotic edible bamboo, Phyllostachys pubescens Mazel ex H. De Lehale (Moso Bamboo) using seeds.25060262Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ETCancer prevention research (Philadelphia, Pa.)Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila). 2014 Oct; 7(10):973-92.Cancer Prev Res (Phila)2014-07-24T00:00:002014Convergence of nanotechnology and cancer prevention: are we there yet?25141546Sareen B, Bhattacharya A, Sharma M, Sood A, Ahuja PSIndian journal of experimental biologyA simple technique for tracking individual spore and gametophyte development in Adiantum lunulatum Burm. f. using modified extra thin alginate film technique. Indian J Exp Biol. 2014 Aug; 52(8):820-4.Indian J Exp Biol2014-08-01T00:00:002014A simple technique for tracking individual spore and gametophyte development in Adiantum lunulatum Burm. f. using modified extra thin alginate film technique.25141547Kaur D, Thapa P, Sharma M, Bhattacharya A, Sood AIndian journal of experimental biologyIn vitro flowering--a system for tracking floral organ development in Dendrocalamus hamiltonii Nees et Arn. ex Munro. Indian J Exp Biol. 2014 Aug; 52(8):825-34.Indian J Exp Biol2014-08-01T00:00:002014In vitro flowering--a system for tracking floral organ development in Dendrocalamus hamiltonii Nees et Arn. ex Munro.25176654Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu XCell reportsThe RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Rep. 2014 Sep 11; 8(5):1447-60.Cell Rep2014-08-28T00:00:002014The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression.25193509Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein GMolecular cancer therapeuticsBisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2583-94.Mol Cancer Ther2014-09-05T00:00:002014Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.25201825Bhandawat A, Sharma V, Sharma H, Sood A, Sharma RKJournal of geneticsDevelopment and crosstransferability of functionally relevant microsatellite markers in Dendrocalamus latiflorus and related bamboo species. J Genet. 2014 Jul 24; 93(2):e48-55.J Genet2014-07-24T00:00:002014Development and crosstransferability of functionally relevant microsatellite markers in Dendrocalamus latiflorus and related bamboo species.25230372Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang WThe Journal of pathologyMiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015 Jan; 235(1):25-36.J Pathol2014-11-06T00:00:002014MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.25277212Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SCNature communicationsCalcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.Nat Commun2014-10-03T00:00:002014Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.25281617Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AKMolecular cancer therapeuticsTherapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85.Mol Cancer Ther2014-10-03T00:00:002014Therapeutic silencing of KRAS using systemically delivered siRNAs.25325936Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen LCurrent oncology reportsMind-body practices in cancer care. Curr Oncol Rep. 2014 Dec; 16(12):417.Curr Oncol Rep2014-12-01T00:00:002014Mind-body practices in cancer care.25351346Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AKNature communicationsHypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202.Nat Commun2014-10-29T00:00:002014Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.25351418van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BGNature communicationsHypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014 Oct 29; 5:5203.Nat Commun2014-10-29T00:00:002014Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.25388163Previs RA, Coleman RL, Harris AL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015 Mar 01; 21(5):955-61.Clin Cancer Res2014-11-11T00:00:002014Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.25416196Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchImmunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59.Clin Cancer Res2014-11-21T00:00:002014Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.25473001Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchDifferential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res. 2015 Feb 01; 21(3):602-10.Clin Cancer Res2014-12-03T00:00:002014Differential platelet levels affect response to taxane-based therapy in ovarian cancer.25475561Kaur D, Dogra V, Thapa P, Bhattacharya A, Sood A, Sreenivasulu YProteomicsIn vitro flowering associated protein changes in Dendrocalamus hamiltonii. Proteomics. 2015 Apr; 15(7):1291-306.Proteomics2015-02-11T00:00:002015In vitro flowering associated protein changes in Dendrocalamus hamiltonii.25477184Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, Blake P, Chirina P, Oh Jeong J, Lim H, Goy A, Pecora A, Suh KSJournal of ovarian researchKallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 2014 Dec 05; 7:109.J Ovarian Res2014-12-05T00:00:002014Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.25497604Matsuo K, Yoshino K, Hasegawa K, Murakami R, Ikeda Y, Adachi S, Hiramatsu K, Yokoyama T, Nishimura M, Sheridan TB, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Fotopoulou C, Roman LD, Sood AKGynecologic oncologySurvival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. Gynecol Oncol. 2015 Feb; 136(2):198-204.Gynecol Oncol2014-12-10T00:00:002014Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.25502429Yang X, Shen F, Hu W, Coleman RL, Sood AKCurrent opinion in obstetrics & gynecologyNew ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65.Curr Opin Obstet Gynecol2015-02-01T00:00:002015New ways to successfully target tumor vasculature in ovarian cancer.25537774Srivastava A, Filant J, Moxley KM, Sood A, McMeekin S, Ramesh RCurrent gene therapyExosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Curr Gene Ther. 2015; 15(2):182-92.Curr Gene Ther2015-01-01T00:00:002015Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment.25544368Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AKCancer metastasis reviewsAnti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015 Mar; 34(1):19-40.Cancer Metastasis Rev2015-03-01T00:00:002015Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.25556616Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, Mezzanzanica D, Chen KX, Sood AK, Yang D, Zhang WChinese journal of cancerKey nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer. 2015 Jan; 34(1):28-40.Chin J Cancer2015-01-01T00:00:002015Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer.25595279Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer ResearchRac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015 May 01; 21(9):2127-37.Clin Cancer Res2015-01-16T00:00:002015Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.25647344Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SKPsychoneuroendocrinologyDiurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology. 2015 Mar; 53:256-67.Psychoneuroendocrinology2015-01-20T00:00:002015Diurnal cortisol and survival in epithelial ovarian cancer.25666164Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein GAdvanced drug delivery reviewsPreclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19.Adv Drug Deliv Rev2015-02-07T00:00:002015Preclinical and clinical development of siRNA-based therapeutics.25680860Jin Y, Wang L, Qu S, Sheng X, Kristian A, M?landsmo GM, P?llmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, W?hre H, Danielsen HE, Ozpolat B, Saatcioglu FEMBO molecular medicineSTAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med. 2015 Mar; 7(3):315-31.EMBO Mol Med2015-03-01T00:00:002015STAMP2 increases oxidative stress and is critical for prostate cancer.25686251Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli MNature cell biologyReduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 2015 Mar; 17(3):311-21.Nat Cell Biol2015-02-16T00:00:002015Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.25707631Nick AM, Coleman RL, Ramirez PT, Sood AKNature reviews. Clinical oncologyA framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015 Apr; 12(4):239-45.Nat Rev Clin Oncol2015-02-24T00:00:002015A framework for a personalized surgical approach to ovarian cancer.25738355Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein GOncotargetAdrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 2015 Feb 28; 6(6):4266-73.Oncotarget2015-02-28T00:00:002015Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.25827290G?mez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PTGynecologic oncologyPredictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8.Gynecol Oncol2015-03-28T00:00:002015Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.25833835Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AKMolecular cancer therapeuticsPTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475.Mol Cancer Ther2015-04-01T00:00:002015PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.25878333Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchXPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97.Clin Cancer Res2015-04-15T00:00:002015XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.25945542Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, Sood A, Lee MHCell cycle (Georgetown, Tex.)Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle. 2015; 14(14):2265-73.Cell Cycle2015-05-06T00:00:002015Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.25989110Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SKBrain, behavior, and immunityBiobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain Behav Immun. 2015 Nov; 50:58-62.Brain Behav Immun2015-05-16T00:00:002015Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma.25995442Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang WJournal of the National Cancer InstituteAugmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015 Jul; 107(7).J Natl Cancer Inst2015-05-20T00:00:002015Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.26013698Matsuo K, Hom MS, Moeini A, Machida H, Takeshima N, Roman LD, Sood AKGynecologic oncologySignificance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecol Oncol. 2015 Aug; 138(2):332-8.Gynecol Oncol2015-05-23T00:00:002015Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer.26081979Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein GNature communicationsThe ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351.Nat Commun2015-06-17T00:00:002015The ZNF304-integrin axis protects against anoikis in cancer.26096769Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SKCancerEudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer. 2015 Oct 01; 121(19):3543-50.Cancer2015-06-10T00:00:002015Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.26098195Zhou M, Li J, Liang S, Sood AK, Liang D, Li CACS nanoCuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal Therapy. ACS Nano. 2015 Jul 28; 9(7):7085-96.ACS Nano2015-06-22T00:00:002015CuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal Therapy.26098849Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra VPloS oneTumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One. 2015; 10(6):e0131095.PLoS One2015-06-22T00:00:002015Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.26146988Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RCPloS oneCDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS One. 2015; 10(7):e0131833.PLoS One2015-07-06T00:00:002015CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.26166806Graybill W, Sood AK, Monk BJ, Coleman RLGynecologic oncologyState of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015 Aug; 138(2):223-6.Gynecol Oncol2015-07-09T00:00:002015State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer.26180057Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchNanotechnology: Future of Oncotherapy. Clin Cancer Res. 2015 Jul 15; 21(14):3121-30.Clin Cancer Res2015-07-15T00:00:002015Nanotechnology: Future of Oncotherapy.26181259Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang WJAMA oncologyAssociation of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol. 2015 Jul; 1(4):486-94.JAMA Oncol2015-07-01T00:00:002015Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.26227489Reyes-Gonz?lez JM, Armaiz-Pe?a GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarr?a-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mej?a PEMolecular cancer therapeuticsTargeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.Mol Cancer Ther2015-07-30T00:00:002015Targeting c-MYC in Platinum-Resistant Ovarian Cancer.26238017Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AKEuropean journal of cancer (Oxford, England : 1990)Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer. 2015 Sep; 51(14):1978-88.Eur J Cancer2015-07-31T00:00:002015Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.26299593Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AKNature reviews. CancerSympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer. 2015 Sep; 15(9):563-72.Nat Rev Cancer2015-09-01T00:00:002015Sympathetic nervous system regulation of the tumour microenvironment.26301456Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AKCancerClinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 01; 121(19):3444-51.Cancer2015-08-24T00:00:002015Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.26313360Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GEOncotargetChitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77.Oncotarget2015-10-06T00:00:002015Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.26389641Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JSHepatology (Baltimore, Md.)Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 2016 Jan; 63(1):159-72.Hepatology2015-11-26T00:00:002015Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.26443929Thaker PH, Urbauer DL, Sood AKCancerReply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias? Cancer. 2016 Jan 15; 122(2):325-6.Cancer2015-10-07T00:00:002015Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?26449316Huang T, Poole EM, Okereke OI, Kubzansky LD, Eliassen AH, Sood AK, Wang M, Tworoger SSGynecologic oncologyDepression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. Gynecol Oncol. 2015 Dec; 139(3):481-6.Gynecol Oncol2015-10-09T00:00:002015Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies.26461095Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang LCancer cellComprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):529-540.Cancer Cell2015-10-12T00:00:002015Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.26481148Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Pe?a GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AKCancer cellErythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.Cancer Cell2015-10-17T00:00:002015Erythropoietin Stimulates Tumor Growth via EphB4.26493647Bowtell DD, B?hm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FRNature reviews. CancerRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79.Nat Rev Cancer2015-11-01T00:00:002015Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.26516159Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AKMolecular cancer therapeuticsDual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec; 14(12):2677-86.Mol Cancer Ther2015-10-29T00:00:002015Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.26632757Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, Atkinson E, Yusuf SW, Lenihan D, Woods ML, Kies MS, Sood AK, Carmack C, Morrison WH, Gillenwater A, Sturgis EM, Garden ASPsychosomatic medicineDepression and Oropharynx Cancer Outcome. Psychosom Med. 2016 Jan; 78(1):38-48.Psychosom Med2016-01-01T00:00:002016Depression and Oropharynx Cancer Outcome.26648870Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua SFrontiers in pharmacologyAdvances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015; 6:286.Front Pharmacol2015-12-01T00:00:002015Advances and Challenges of Liposome Assisted Drug Delivery.26655797Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar A, Baggerly KA, Sood AK, White MAMolecular systems biologyA genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol. 2015 Dec 11; 11(12):842.Mol Syst Biol2015-12-11T00:00:002015A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.26686630Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AKCell reportsLong Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec 22; 13(11):2395-2402.Cell Rep2015-12-10T00:00:002015Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.26721482Zhang X, Lopez-Berestein G, Sood AK, Calin GAMethods in molecular biology (Clifton, N.J.)Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods Mol Biol. 2016; 1402:33-41.Methods Mol Biol2016-01-01T00:00:002016Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray.26721492Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2016; 1402:189-197.Methods Mol Biol2016-01-01T00:00:002016Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.74Professor10Assistant Professor54Instructor11105046Mayr NA, Yuh WT, Arnholt JC, Ehrhardt JC, Sorosky JI, Magnotta VA, Berbaum KS, Zhen W, Paulino AC, Oberley LW, Sood AK, Buatti JMJournal of magnetic resonance imaging : JMRIPixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging. 2000 Dec; 12(6):1027-33.J Magn Reson Imaging2000-12-01T00:00:002000Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer.CRISTINAIVANCRISTINA IVAN11810IVAN, CRISTINAAssistant ProfessorSHERRYWUSHERRY WU11822WU, SHERRYAssistant Professor26599259Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta LHepatology (Baltimore, Md.)Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology. 2016 Mar; 63(3):864-79.Hepatology2016-01-14T00:00:002016Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.26819345Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AKJournal of the National Cancer InstituteRole of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.J Natl Cancer Inst2016-01-26T00:00:002016Role of Increased n-acetylaspartate Levels in Cancer.26844611Bhalwal AB, Nick AM, Dos Reis R, Chen CL, Munsell MF, Ramalingam P, Salcedo MP, Ramirez PT, Sood AK, Schmeler KMInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyCarcinoma of the Bartholin Gland: A Review of 33 Cases. Int J Gynecol Cancer. 2016 May; 26(4):785-9.Int J Gynecol Cancer2016-05-01T00:00:002016Carcinoma of the Bartholin Gland: A Review of 33 Cases.26968641Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DAGynecologic oncologyCharacteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016 May; 141(2):260-263.Gynecol Oncol2016-03-11T00:00:002016Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.27009216Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AKMolecular cancer therapeuticsDll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. 2016 06; 15(6):1344-52.Mol Cancer Ther2016-03-23T00:00:002016Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.27041221Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AKNature communicationsA miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016 Apr 04; 7:11169.Nat Commun2016-04-04T00:00:002016A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.27064283Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AKThe Journal of clinical investigationFAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 05 02; 126(5):1885-96.J Clin Invest2016-04-11T00:00:002016FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.27300436Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ERCancer cell?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 06 13; 29(6):874-888.Cancer Cell2016-06-13T00:00:002016?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.27453821Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan VBBA clinicalLipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clin. 2016 Dec; 6:76-81.BBA Clin2016-06-30T00:00:002016Lipid profile of platelets and platelet-derived microparticles in ovarian cancer.27036018Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PHOncotargetmiR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2016 May 03; 7(18):25930-48.Oncotarget2016-05-03T00:00:002016miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.18006843Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AKCancer researchTherapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007 Nov 15; 67(22):10976-83.Cancer Res2007-11-15T00:00:002007Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.18182619Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LMJournal of the National Cancer InstituteTherapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.J Natl Cancer Inst2008-01-08T00:00:002008Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.16322684Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AICancer biology & therapyThe role of relaxin in endometrial cancer. Cancer Biol Ther. 2006 Jan; 5(1):71-7.Cancer Biol Ther2006-01-31T00:00:002006The role of relaxin in endometrial cancer.27534811Hu Q, Cho MS, Thiagarajan P, Aung FM, Sood AK, Afshar-Kharghan VPlateletsA small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets. 2017 Jan; 28(1):99-102.Platelets2016-08-18T00:00:002016A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets.22166844Berger JL, Westin SN, Fellman B, Rallapali V, Frumovitz M, Ramirez PT, Sood AK, Soliman PTGynecologic oncologyModified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5.Gynecol Oncol2011-12-11T00:00:002011Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes.22581827Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JSCarcinogenesisFOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012 Oct; 33(10):1843-53.Carcinogenesis2012-05-10T00:00:002012FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.22776561Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AKCancer lettersBiological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9.Cancer Lett2012-07-07T00:00:002012Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma.22966490Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, B?nhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, B?chet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahov? M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronj? MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, D?az-Araya G, D?az-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farr? JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, F?s?s L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et alAutophagyGuidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.Autophagy2012-04-01T00:00:002012Guidelines for the use and interpretation of assays for monitoring autophagy.17306693Frumovitz M, Sood AKGynecologic oncologyVascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol. 2007 Mar; 104(3):768-78.Gynecol Oncol2007-03-01T00:00:002007Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.16963111Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CFGynecologic oncologyLymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.Gynecol Oncol2006-09-11T00:00:002006Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer.18060038Fern?ndez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein GThe Journal of clinical investigationAn anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007 Dec; 117(12):4044-54.J Clin Invest2007-12-01T00:00:002007An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.18806828Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LMOncogeneTherapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008 Dec 04; 27(57):7192-200.Oncogene2008-09-22T00:00:002008Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.19416223Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AIAnnals of the New York Academy of SciencesRelaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.Ann N Y Acad Sci2009-04-01T00:00:002009Relaxin/RXFP1 signaling in prostate cancer progression.27185008Feng S, Kroll MH, Nick AM, Sood AK, Afshar-Kharghan VPlateletsPlatelets are not hyperreactive in patients with ovarian cancer. Platelets. 2016 Nov; 27(7):716-718.Platelets2016-05-16T00:00:002016Platelets are not hyperreactive in patients with ovarian cancer.27829138Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath DCell metabolismTargeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 2016 11 08; 24(5):685-700.Cell Metab2016-11-08T00:00:002016Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.27889101Yatsenko SA, Mittal P, Wood-Trageser MA, Jones MW, Surti U, Edwards RP, Sood AK, Rajkovic AFertility and sterilityHighly heterogeneous genomic landscape of uterine leiomyomas by?whole exome sequencing and genome-wide arrays. Fertil Steril. 2017 02; 107(2):457-466.e9.Fertil Steril2016-11-23T00:00:002016Highly heterogeneous genomic landscape of uterine leiomyomas by?whole exome sequencing and genome-wide arrays.20052724Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AKCancerPelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30.Cancer2010-02-01T00:00:002010Pelvic fractures after radiotherapy for cervical cancer: implications for survivors.20028751Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer Researchc-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.Clin Cancer Res2009-12-22T00:00:002009c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.20332054Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DMGynecologic oncologyUnmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010 Jun; 117(3):491-6.Gynecol Oncol2010-03-23T00:00:002010Unmasking the complexities of mucinous ovarian carcinoma.22063003You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, Liang D, Wei W, Sood AK, Li CJournal of controlled release : official journal of the Controlled Release SocietyPhotothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release. J Control Release. 2012 Mar 10; 158(2):319-28.J Control Release2011-10-28T00:00:002011Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release.27283932Zhou M, Melancon M, Stafford RJ, Li J, Nick AM, Tian M, Sood AK, Li CJournal of nuclear medicine : official publication, Society of Nuclear MedicinePrecision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy. J Nucl Med. 2016 Nov; 57(11):1778-1783.J Nucl Med2016-06-09T00:00:002016Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy.21737505Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011 Aug 15; 17(16):5367-78.Clin Cancer Res2011-07-07T00:00:002011Targeting SRC in mucinous ovarian carcinoma.22210309Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJGynecologic oncologyProceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7.Gynecol Oncol2011-12-28T00:00:002011Proceedings from the 9th International Conference on Ovarian Cancer.22335738Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AKThe New England journal of medicineParaneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8.N Engl J Med2012-02-16T00:00:002012Paraneoplastic thrombocytosis in ovarian cancer.Authorship 84166022353948Frumovitz M, Kriseman ML, Sun CC, Blumenthal-Barby J, Sood AK, Bodurka DC, Soliman PTObstetrics and gynecologyUnverifiable accomplishments and publications on applications for gynecologic oncology fellowships. Obstet Gynecol. 2012 Mar; 119(3):504-8.Obstet Gynecol2012-03-01T00:00:002012Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships.Authorship 841787Authorship 841810Authorship 842041Authorship 842331Authorship 842388Authorship 842448Authorship 842500Authorship 842735Authorship 842893Authorship 843055Authorship 843695Authorship 843709Authorship 843867Authorship 844920Authorship 844929Authorship 844991Authorship 845313Authorship 845459Authorship 845529Authorship 845661Authorship 845715Authorship 845957Authorship 846124Authorship 846436Authorship 846478Authorship 846637Authorship 846664Authorship 846785Authorship 846843Authorship 846844Authorship 846856Authorship 847019Authorship 847319Authorship 847987Authorship 848216Authorship 848479Authorship 848566Authorship 848807Authorship 849011Authorship 849369Authorship 849646Authorship 849674Authorship 849816Authorship 850017Authorship 850317Authorship 850385Authorship 850549Authorship 850861Authorship 850866Authorship 850975Authorship 851759Authorship 851869Authorship 852145Authorship 852888Authorship 853229Authorship 853537Authorship 853576Authorship 853645Authorship 853720Authorship 854282Authorship 854843Authorship 854881Authorship 855085Authorship 855663Authorship 856017Authorship 856336Authorship 856906Authorship 856953Authorship 857296Authorship 857430Authorship 857623Authorship 857755Authorship 857916Authorship 858018Authorship 858153Authorship 858313Authorship 858416Authorship 858447Authorship 858568Authorship 858935Authorship 859250Authorship 859360Authorship 859499Authorship 859546Authorship 859879Authorship 860210Authorship 860441Authorship 860774Authorship 860965Authorship 861076Authorship 861356Authorship 861378Authorship 861661Authorship 861926Authorship 862033Authorship 862338Authorship 862513Authorship 862543Authorship 862817Authorship 863048Authorship 863308Authorship 863526Authorship 863879Authorship 864150Authorship 864509Authorship 865148Authorship 865149Authorship 865289Authorship 865335Authorship 865444Authorship 865998Authorship 866067Authorship 866308Authorship 866409Authorship 866443Authorship 866626Authorship 866818Authorship 866859Authorship 866878Authorship 867228Authorship 867678Authorship 867716Authorship 867797Authorship 867892Authorship 867960Authorship 868048Authorship 868206Journal of ImmunologyComplement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition. Journal of Immunology. 196:1412-1418.Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transitionBBA ClinicalLipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clinical. 6:76-81.Lipid profile of platelets and platelet-derived microparticles in ovarian cancerCell ReportsRole of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17:1621-1631.Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine CancersOncologyThe Kim/Alvarez article reviewed. Oncology. 14:1336-1338.The Kim/Alvarez article reviewedCell ReportsLong Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. 13:2395-2402.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering GlycolysisFuture OncologyEvaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncology. 12:1439-1456.Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapyTargeted Therapy and Molecular Genetics. 539-560.Targeted Therapy and Molecular GeneticsOncogeneGrb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancerMolecular Cancer TherapeuticsPTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer. Molecular Cancer Therapeutics. 14:1466-1475.PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancerNatureTP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520:697-701.TP53 loss creates therapeutic vulnerability in colorectal cancerAdvances in Experimental Medicine and BiologyClassification of ovarian cancer. Advances in Experimental Medicine and Biology. 622:23-33.Classification of ovarian cancerClinical Cancer ResearchAdrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research. 22:1713-1724.Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancerJournal of the American Veterinary Medical AssociationPathology in practice. Journal of the American Veterinary Medical Association. 249:1149-1151.Pathology in practiceOncogeneAntiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4Gynecologic OncologyCopy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecologic Oncology. 141:57-64.Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancerACS NanoCuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal Therapy. ACS Nano. 9:7085-7096.CuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal TherapyOncogeneHypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progressionNature CommunicationsA miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7.A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancerContemporary Reviews in Obstetrics and GynaecologyThe value of CA-125 levels in the management of endometrial cancer. Contemporary Reviews in Obstetrics and Gynaecology. 10:135-140.The value of CA-125 levels in the management of endometrial cancerCancerEudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer. 121:3543-3550.Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancerBrain, Behavior, and ImmunityBiobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain, Behavior, and Immunity. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinomaScientific ReportsIn vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Scientific Reports. 6.In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapyTargeting therapies in cancer. 167-182.Targeting therapies in cancerCancer CellSalt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic NicheJournal of Clinical InvestigationFAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation. 126:1885-1896.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawalJAMA - Journal of the American Medical AssociationBRCA1 and BRCA2 mutations in ovarian cancer - Reply. JAMA - Journal of the American Medical Association. 307:360-361.BRCA1 and BRCA2 mutations in ovarian cancer - ReplyHepatologyYes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 63:159-172.Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinomaCancer ResearchBET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Research. 76:6320-6330.BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancerNature CommunicationsThe ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6.The ZNF304-integrin axis protects against anoikis in cancerInternational Journal of Gynecological CancerRole of video-assisted thoracoscopy in advanced ovarian cancer. International Journal of Gynecological Cancer. 26:801-806.Role of video-assisted thoracoscopy in advanced ovarian cancerHepatologyDifferentiation therapy for hepatocellular carcinoma. Hepatology. Differentiation therapy for hepatocellular carcinomaCancer Biology and TherapyStress and the spread of ovarian cancer in mice. Cancer Biology and Therapy. 5:898.Stress and the spread of ovarian cancer in miceCancer ResearchUbiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research. 76:7194-7207.Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cellsCurrent Oncology ReportsMind-Body Practices in Cancer Care. Current Oncology Reports. 16.Mind-Body Practices in Cancer CareCancer DiscoveryMiRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discovery. 6:235-246.MiRNA deregulation in cancer cells and the tumor microenvironmentJournal of PathologyMIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. Journal of Pathology. 241:67-79.MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancerJournal of Hematology and OncologyMIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology and Oncology. 9.MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasisNeuroendocrine regulation of cancer progression. 233-249.Neuroendocrine regulation of cancer progressionBioTechniquesMorph-X-select. BioTechniques. 61:249-259.Morph-X-selectJournal of Pelvic Medicine and SurgeryPolypropylene mesh erosion into the bowel and vagina after abdominal sacral colpopexy. Journal of Pelvic Medicine and Surgery. 12:45-47.Polypropylene mesh erosion into the bowel and vagina after abdominal sacral colpopexyJournal of Nuclear MedicinePrecision nanomedicine using dual PET and MR temperature imaging-guided photothermal therapy. Journal of Nuclear Medicine. 57:1778-1783.Precision nanomedicine using dual PET and MR temperature imaging-guided photothermal therapyPsychoneuroimmunology and Cancer. Psychoneuroimmunology and CancerPlateletsPlatelets are not hyperreactive in patients with ovarian cancer. Platelets. 1-3.Platelets are not hyperreactive in patients with ovarian cancerInternational Journal of Gynecological PathologyErratum. International Journal of Gynecological Pathology. 26:205.ErratumNature Reviews CancerRethinking ovarian cancer II. Nature Reviews Cancer. 15:668-679.Rethinking ovarian cancer IIPlateletsA small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets. 1-4.A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in plateletsPLoS OneRegulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT ativation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS One. 10.Regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT ativation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosisFrontiers in PharmacologyAdvances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 6.Advances and challenges of liposome assisted drug deliveryAdvanced Drug Delivery ReviewsPreclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews. Preclinical and clinical development of siRNA-based therapeuticsInternational Journal of Gynecological CancerCarcinoma of the bartholin gland. International Journal of Gynecological Cancer. 26:785-789.Carcinoma of the bartholin glandJournal of Clinical InvestigationErratum. Journal of Clinical Investigation. 123:4980.ErratumCancer Epidemiology Biomarkers and PreventionCancer Epidemiology Biomarkers and Prevention. 25:1587-1594.Cancer Epidemiology Biomarkers and PreventionClinical Cancer ResearchMolecular pathways. Clinical Cancer Research. 21:955-961.Molecular pathwaysCell CycleRegulating the stability and localization of CDK inhibitor p27<sup>Kip1</sup> via CSN6-COP1 axis. Cell Cycle. 14:2265-2273.Regulating the stability and localization of CDK inhibitor p27<sup>Kip1</sup> via CSN6-COP1 axisOncotargetTherapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 7:15093-15104.Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancerCancer Treatment ReviewsRNA-targeted therapeutics in cancer clinical trials. Cancer Treatment Reviews. 50:35-47.RNA-targeted therapeutics in cancer clinical trialsNucleic Acids ResearchEvoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Research. 44:8052-8064.Evoking picomolar binding in RNA by a single phosphorodithioate linkageNew England Journal of MedicineDicer and Drosha in Ovarian Cancer. New England Journal of Medicine. 360:1151.Dicer and Drosha in Ovarian CancerJournal of Gynecologic SurgeryMetastatic Breast Cancer to the Uterus and Cervix. Journal of Gynecologic Surgery. 19:145-147.Metastatic Breast Cancer to the Uterus and CervixInhibition of the src oncogene. 95-107.Inhibition of the src oncogeneMolecular Cancer TherapeuticsDll4 Inhibition plus Aflibercept markedly reduces ovarian tumor growth. Molecular Cancer Therapeutics. 15:1344-1352.Dll4 Inhibition plus Aflibercept markedly reduces ovarian tumor growthCell MetabolismTargeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24:685-700.Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell GrowthGynecologic OncologyDepression and risk of epithelial ovarian cancer. Gynecologic Oncology. 139:481-486.Depression and risk of epithelial ovarian cancerMolecular Cancer TherapeuticsAntitumor and antiangiogenic effects of aspirin-PC in ovarian cancer. Molecular Cancer Therapeutics. 15:2894-2904.Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancerMolecular Cancer TherapeuticsTargeting c-MYC in platinum-resistant ovarian cancer. Molecular Cancer Therapeutics. 14:2260-2269.Targeting c-MYC in platinum-resistant ovarian cancerRNAi in Cancer Therapy. 271-307.RNAi in Cancer TherapyCancer CellIntegrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer [Cancer Cell 23 (2013) 186-199]. Cancer Cell. 23:705.Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer [Cancer Cell 23 (2013) 186-199]New England Journal of MedicineThe authors reply. New England Journal of Medicine. 366:1840.The authors replyDeveloping hyperpolarized silicon particles for advanced biomedical imaging applications. Developing hyperpolarized silicon particles for advanced biomedical imaging applicationsJournal of Gynecologic TechniquesOgilvie's syndrome complicating low colorectal anastomosis 3 years after intraperitoneal <sup>32</sup>P. Journal of Gynecologic Techniques. 6:65-67.Ogilvie's syndrome complicating low colorectal anastomosis 3 years after intraperitoneal <sup>32</sup>PPsychosomatic MedicineDepression and oropharynx cancer outcome. Psychosomatic Medicine. 78:38-48.Depression and oropharynx cancer outcomeClinical Cancer ResearchNanotechnology. Clinical Cancer Research. 21:3121-3130.NanotechnologyOncogeneErratum. Oncogene. 35:801.ErratumCell MetabolismSnapShot. Cell Metabolism. 23:388-388e1.SnapShotCancerClinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 121:3444-3451.Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancerCancer ResearchThrombosis in cancer. Cancer Research. 76:3671-3675.Thrombosis in cancerJournal of Medical ImagingDeveloping hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. Journal of Medical Imaging. 3.Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancerNutrition in Clinical PracticeNasoenteric Tube Complication. Nutrition in Clinical Practice. 13:40-42.Nasoenteric Tube ComplicationFrontiers in OncologyEnhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells. Frontiers in Oncology. 3 MAR.Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cellsInternational Journal of CancerHypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. International Journal of Cancer. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancerCancer Causes and ControlA prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes and Control. 27:661-668.A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patientsAssessment of In vivo siRNA delivery in cancer mouse models. 189-197.Assessment of In vivo siRNA delivery in cancer mouse modelsJAMA oncologyAssociation of somatic mutations of ADAMTS genes with chemotherapy sensitivity and survival in high-grade serous ovarian carcinoma. JAMA oncology. 1:486-494.Association of somatic mutations of ADAMTS genes with chemotherapy sensitivity and survival in high-grade serous ovarian carcinomaExpert Review of Molecular DiagnosticsThe rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics. 16:1337-1351.The rise of genomic profiling in ovarian cancerEuropean Journal of CancerTargeting the tumour microenvironment in ovarian cancer. European Journal of Cancer. 56:131-143.Targeting the tumour microenvironment in ovarian cancerProceedings of the National Academy of Sciences of the United States of AmericaElectron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 112:14266-14271.Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancerInfectious Diseases in Obstetrics and GynecologyHuman Papillomavirus DNA in LEEP Plume. Infectious Diseases in Obstetrics and Gynecology. 2:167-170.Human Papillomavirus DNA in LEEP PlumeJournal of Clinical InvestigationErratum. Journal of Clinical Investigation. 123:5411.ErratumInternational Journal of NanomedicineToll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. International Journal of Nanomedicine. 11:5729-5742.Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapyGynecologic OncologyErratum. Gynecologic Oncology. 130:252-253.ErratumOncotargetSSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget. 7:33179-33191.SSRI use and clinical outcomes in epithelial ovarian cancerGynecologic OncologyTEMPORARY REMOVAL. Gynecologic Oncology. TEMPORARY REMOVALJournal of the National Cancer InstituteRole of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108.Role of Increased n-acetylaspartate Levels in CancerMolecular Systems BiologyA genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Molecular Systems Biology. 11:1-17.A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpressionOncogeneTargeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3pGynecologic OncologyCharacteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecologic Oncology. Characteristics of 10-year survivors of high-grade serous ovarian carcinomaCancer and Metastasis ReviewsAnti-vascular therapies in ovarian cancer. Cancer and Metastasis Reviews. 34:19-40.Anti-vascular therapies in ovarian cancerMolecular Cancer TherapeuticsDual metronomic chemotherapy with nab-paclitaxel and topotecan has potent antiangiogenic activity in ovarian cancer. Molecular Cancer Therapeutics. 14:2677-2686.Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent antiangiogenic activity in ovarian cancerOncotargetNO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. Oncotarget. 7:47576-47585.NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamilMolecular Therapy - Nucleic AcidsTherapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Molecular Therapy - Nucleic Acids. 2.Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancerObstetrics and GynecologyAssociation of low-dose aspirin and survival of women with endometrial cancer. Obstetrics and Gynecology. 128:127-137.Association of low-dose aspirin and survival of women with endometrial cancerOncotargetReciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 7:20825-20839.Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2Profiling long noncoding RNA expression using custom-designed microarray. 33-41.Profiling long noncoding RNA expression using custom-designed microarrayClinical Cancer ResearchRac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clinical Cancer Research. 21:2127-2137.Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancerExpert Opinion on Investigational DrugsImmunological and pleiotropic effects of individual β-blockers and their relevance in cancer therapies. Expert Opinion on Investigational Drugs. 1-5.Immunological and pleiotropic effects of individual β-blockers and their relevance in cancer therapiesScientific ReportsMultimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent. Scientific Reports. 6.Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast AgentCell ReportsDirect Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. 15:1493-1504.Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian CancerCancer CellErythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.Erythropoietin Stimulates Tumor Growth via EphB4OncogeneSustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesisCME Journal of Gynecologic OncologyLoss of heterozygosity (LOH) as a prognostic factor in ovarian cancer. CME Journal of Gynecologic Oncology. 4:189-191.Loss of heterozygosity (LOH) as a prognostic factor in ovarian cancerJournal of Gynecologic SurgeryPrimary ovarian leiomyomas. Journal of Gynecologic Surgery. 15:55-59.Primary ovarian leiomyomasMolecular Cancer TherapeuticsLinalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Molecular Cancer Therapeutics. 15:618-627.Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinomaCancer CellComprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 28:529-540.Comprehensive Genomic Characterization of Long Non-coding RNAs across Human CancersBiology and genetics. 2-38.Biology and geneticsEBioMedicineEBioMedicine. 12:34-42.EBioMedicinePLoS OneTumor T<inf>1</inf> relaxation time for assessing response to bevacizumab anti-angiogenic therapy in a mouse ovarian cancer model. PLoS One. 10.Tumor T<inf>1</inf> relaxation time for assessing response to bevacizumab anti-angiogenic therapy in a mouse ovarian cancer modelOncotargetmiR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 7:25930-25948.miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancerTargeting approaches for nanoparticles. 64-77.Targeting approaches for nanoparticlesOncotargetContinuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancerCancer CellCancer Cell. 29:874-888.Cancer CellBreast Cancer ResearchCorrection. Breast Cancer Research. 14.CorrectionCurrent Cancer Therapy ReviewsStress related neuroendocrine influences in ovarian cancer. Current Cancer Therapy Reviews. 8:100-109.Stress related neuroendocrine influences in ovarian cancerClinical Cancer ResearchXPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research. 21:3286-3297.XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5AObstetrical and Gynecological SurveyAssociation of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Obstetrical and Gynecological Survey. 67:164-165.Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancerFertility and SterilityHighly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertility and Sterility. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arraysNature CommunicationsErratum. Nature Communications. 4.ErratumOncotargetChitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 6:29161-29177.Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagyNature Reviews Disease PrimersOvarian cancer. Nature Reviews Disease Primers. 2:1-22.Ovarian cancer23052253Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann MClinical cancer research : an official journal of the American Association for Cancer ResearchHighly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.Clin Cancer Res2012-10-10T00:00:002012Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.28411194Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang HGenome researchSystematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017 07; 27(7):1112-1125.Genome Res2017-04-14T00:00:002017Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.28403581Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PHOncotargetCorrection: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2017 03 07; 8(10):17406.Oncotarget2017-03-07T00:00:002017Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.28698296Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin LGenes & developmentPRKCI promotes immune suppression in ovarian cancer. Genes Dev. 2017 06 01; 31(11):1109-1121.Genes Dev2017-06-01T00:00:002017PRKCI promotes immune suppression in ovarian cancer.28774461Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AKGynecologic oncologyPhase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46.Gynecol Oncol2017-08-01T00:00:002017Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.20664385Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PTObstetrics and gynecologyPrevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-273.Obstet Gynecol2010-08-01T00:00:002010Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.20861284Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AIEndocrine-related cancerSuppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.Endocr Relat Cancer2010-10-29T00:00:002010Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.22966171Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan VBloodPlatelets increase the proliferation of ovarian cancer cells. Blood. 2012 Dec 06; 120(24):4869-72.Blood2012-09-10T00:00:002012Platelets increase the proliferation of ovarian cancer cells.29622464Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani RCancer cellA Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018 04 09; 33(4):690-705.e9.Cancer Cell2018-04-02T00:00:002018A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.29617668Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Cancer Genome Atlas Research Network, Sood AK, Gunaratne PH, Sumazin PCell reportsPan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep. 2018 04 03; 23(1):297-312.e12.Cell Rep2018-04-03T00:00:002018Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.29267866McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu PJournal of the National Cancer InstituteThe Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst. 2018 07 01; 110(7):777-786.J Natl Cancer Inst2018-07-01T00:00:002018The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.29130936Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin CThe Journal of clinical investigationJAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.J Clin Invest2017-11-13T00:00:002017JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.29249663Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JCStem cell reportsHN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. 2018 01 09; 10(1):212-227.Stem Cell Reports2017-12-14T00:00:002017HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.29669287Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma LCell reportsZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep. 2018 Apr 17; 23(3):823-837.Cell Rep2018-04-17T00:00:002018ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.Authorship 8870528Authorship 88732333Authorship 88741317Authorship 88753025Authorship 88794311Authorship 88851511Authorship 88851926Authorship 8885387Authorship 88859725Authorship 8886651664Authorship 88874421Authorship 88881437Authorship 88882024Authorship 8891477Authorship 88916928Authorship 8892067Authorship 8892704Authorship 8893669Authorship 88937618Authorship 8894945Authorship 8895518Authorship 8896909Authorship 88991122Authorship 88991224Authorship 89013326Authorship 89020014D036104Chemicals & Drugs631320.893665Receptor, EphA2D034741Chemicals & Drugs77922170.625403RNA, Small InterferingD010051Disorders61946210.315794Ovarian NeoplasmsD009389Disorders52015470.58592Neovascularization, PathologicD009375Disorders1895190.693247Neoplasms, Glandular and EpithelialAuthorship 9041897Authorship 90443810Authorship 9044903Authorship 90457918Authorship 9046362Authorship 9047399Authorship 90495131Authorship 90510818Authorship 90568111Authorship 90588011Authorship 9059006Authorship 9066023Authorship 9066893Authorship 90729115Authorship 90773113Authorship 90784029Authorship 9080612Authorship 9081232Authorship 9081398Authorship 90854712Authorship 9085933Authorship 90884715Authorship 9089485Authorship 9092805Authorship 9092814Authorship 90953911Authorship 9095859Authorship 90966215Authorship 90977815Authorship 90997633Authorship 9100375Authorship 91054512Authorship 9105923Authorship 9107226Authorship 9107523Authorship 9110345Authorship 9110803Authorship 9119719Authorship 9121673Authorship 9124158Authorship 9126352Authorship 9128137Authorship 9129218Authorship 9130716Authorship 9131399Authorship 91324116Authorship 9137077Authorship 91385810Authorship 9141498Authorship 91445931Authorship 91455320Authorship 9145806Authorship 91460024Authorship 91483223Authorship 9148644Authorship 9160429Authorship 91616415Authorship 91636511Authorship 91704719Authorship 91705315Authorship 91715414Authorship 91769617Authorship 9177305Authorship 9181887Authorship 91849225Authorship 9185772Authorship 9186843Authorship 91880912Authorship 91905525Authorship 91931910Authorship 9194454Authorship 9194944Authorship 9195025Authorship 91970313Authorship 91974435Authorship 91998012Authorship 92031429Authorship 92057416Authorship 9208836Authorship 92098425Authorship 92098933Authorship 92162714Authorship 9217297Authorship 92179218Authorship 92183736Authorship 9222624Authorship 9222662Authorship 9223126Authorship 9224287Authorship 9232714Authorship 92345625Authorship 92354026Authorship 9238038Authorship 9247059Authorship 9249719Authorship 92515413Authorship 9254039Authorship 92592521Authorship 92605417Authorship 92646511Authorship 9270879Authorship 92735021Authorship 9274298Authorship 9275407Authorship 9276619Authorship 9281739Authorship 9281856Authorship 9293503Authorship 9294667Authorship 92991630Authorship 9302998Authorship 9303106Authorship 93062715Authorship 9309023Authorship 93139016Authorship 9320596Authorship 93321914Authorship 9339875Authorship 9342719Authorship 93430211Authorship 9346962Authorship 93484519Authorship 93516011Authorship 9352918Authorship 9353404Authorship 9353435Authorship 93601622Authorship 93603625Authorship 9364813Authorship 9382723Authorship 93859011Authorship 93936715Authorship 93938328Authorship 940232226388704Jiang L, Nick AM, Sood AKCurrent anesthesiology reportsFundamental Principles of Cancer Biology: Does it have relevance to the perioperative period? Curr Anesthesiol Rep. 2015 Sep; 5(3):250-256.Curr Anesthesiol Rep2015-09-01T00:00:002015Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?26954371Chung JF, Lee SJ, Sood AKExpert opinion on investigational drugsImmunological and pleiotropic effects of individual ?-blockers and their relevance in cancer therapies. Expert Opin Investig Drugs. 2016; 25(5):501-5.Expert Opin Investig Drugs2016-03-22T00:00:002016Immunological and pleiotropic effects of individual ?-blockers and their relevance in cancer therapies.26959114Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JDOncotargetReciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 2016 Apr 12; 7(15):20825-39.Oncotarget2016-04-12T00:00:002016Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.27016230Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang DGynecologic oncologyCopy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol. 2016 Apr; 141(1):57-64.Gynecol Oncol2016-04-01T00:00:002016Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.27023470Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SSCancer causes & control : CCCA prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes Control. 2016 May; 27(5):661-8.Cancer Causes Control2016-03-29T00:00:002016A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients.26748214Mitamura T, Gourley C, Sood AKGynecologic oncologyPrediction of anti-angiogenesis escape. Gynecol Oncol. 2016 Apr; 141(1):80-5.Gynecol Oncol2015-12-31T00:00:002015Prediction of anti-angiogenesis escape.26863488Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AKCell metabolismSnapShot: Stress and Disease. Cell Metab. 2016 Feb 09; 23(2):388-388.e1.Cell Metab2016-02-09T00:00:002016SnapShot: Stress and Disease.26865249Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AKCancer discoverymiRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016 Mar; 6(3):235-46.Cancer Discov2016-02-10T00:00:002016miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.26929586Srivastava S, Misra A, Kumar D, Srivastava A, Sood A, Rawat APharmacognosy magazineReversed-phase high-performance Liquid Chromatography-ultraviolet Photodiode Array Detector Validated Simultaneous Quantification of six Bioactive Phenolic Acids in Roscoea purpurea Tubers and their In vitro Cytotoxic Potential against Various Cell Lines. Pharmacogn Mag. 2015 Oct; 11(Suppl 3):S488-95.Pharmacogn Mag2015-10-01T00:00:002015Reversed-phase high-performance Liquid Chromatography-ultraviolet Photodiode Array Detector Validated Simultaneous Quantification of six Bioactive Phenolic Acids in Roscoea purpurea Tubers and their In vitro Cytotoxic Potential against Various Cell Lines.26934358Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SSInternational journal of cancerHypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. Int J Cancer. 2016 07 15; 139(2):291-9.Int J Cancer2016-03-25T00:00:002016Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer.26937753Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PTInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyRole of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6.Int J Gynecol Cancer2016-05-01T00:00:002016Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review.26581245Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchAdrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1713-24.Clin Cancer Res2015-11-18T00:00:002015Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.26718342Cho MS, Rupaimoole R, Choi HJ, Noh K, Chen J, Hu Q, Sood AK, Afshar-Kharghan VJournal of immunology (Baltimore, Md. : 1950)Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. J Immunol. 2016 Feb 01; 196(3):1412-8.J Immunol2015-12-30T00:00:002015Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.26849037Hansen JM, Coleman RL, Sood AKEuropean journal of cancer (Oxford, England : 1990)Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016 Mar; 56:131-143.Eur J Cancer2016-02-03T00:00:002016Targeting the tumour microenvironment in ovarian cancer.26861249Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JWMolecular cancer therapeuticsLinalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Mol Cancer Ther. 2016 04; 15(4):618-27.Mol Cancer Ther2016-02-09T00:00:002016Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.26918603Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya ROncotargetTherapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.Oncotarget2016-03-22T00:00:002016Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.27087632Jenner ZB, Sood AK, Coleman RLFuture oncology (London, England)Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun; 12(12):1439-56.Future Oncol2016-04-18T00:00:002016Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.27160903Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GBCell reportsDirect Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep. 2016 05 17; 15(7):1493-1504.Cell Rep2016-05-05T00:00:002016Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.27382431Zhang S, Mercado-Uribe I, Sood A, Bast RC, Liu JGenes & cancerCoevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer. 2016 Mar; 7(3-4):60-72.Genes Cancer2016-03-01T00:00:002016Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells.27527638Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AKCancer researchThrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 07 01; 76(13):3671-5.Cancer Res2016-06-20T00:00:002016Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group.27147567Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu SOncotargetContinuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.Oncotarget2016-06-07T00:00:002016Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.27374093Chung JF, Yoon CJ, Cheon SA, Seo ES, Park SH, Yang JS, Kim B, Joo MY, Park TJ, Kim KH, Sood AK, Lee SJOncotargetNO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. Oncotarget. 2016 Jul 26; 7(30):47576-47585.Oncotarget2016-07-26T00:00:002016NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil.27638860Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AKMolecular cancer therapeuticsAntitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther. 2016 12; 15(12):2894-2904.Mol Cancer Ther2016-09-16T00:00:002016Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.27121207Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, Sood AK, Lutgendorf SKOncotargetSSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget. 2016 May 31; 7(22):33179-91.Oncotarget2016-05-31T00:00:002016SSRI use and clinical outcomes in epithelial ovarian cancer.27275802Matsuo K, Cahoon SS, Yoshihara K, Shida M, Kakuda M, Adachi S, Moeini A, Machida H, Garcia-Sayre J, Ueda Y, Enomoto T, Mikami M, Roman LD, Sood AKObstetrics and gynecologyAssociation of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstet Gynecol. 2016 Jul; 128(1):127-137.Obstet Gynecol2016-07-01T00:00:002016Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.27558151Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BYNature reviews. Disease primersOvarian cancer. Nat Rev Dis Primers. 2016 08 25; 2:16061.Nat Rev Dis Primers2016-08-25T00:00:002016Ovarian cancer.27566147Abeydeera ND, Egli M, Cox N, Mercier K, Conde JN, Pallan PS, Mizurini DM, Sierant M, Hibti FE, Hassell T, Wang T, Liu FW, Liu HM, Martinez C, Sood AK, Lybrand TP, Frydman C, Monteiro RQ, Gomer RH, Nawrot B, Yang XNucleic acids researchEvoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Res. 2016 09 30; 44(17):8052-64.Nucleic Acids Res2016-08-26T00:00:002016Evoking picomolar binding in RNA by a single phosphorodithioate linkage.27319211Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, Sood AK, McMeekin S, Ramesh RJournal of biomedical nanotechnologyExploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. J Biomed Nanotechnol. 2016 Jun; 12(6):1159-73.J Biomed Nanotechnol2016-06-01T00:00:002016Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer.27478041Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Carrami EM, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AACancer cellSalt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. 2016 08 08; 30(2):273-289.Cancer Cell2016-07-28T00:00:002016Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.27587791Huang T, Tworoger SS, Hecht JL, Rice MS, Sood AK, Kubzansky LD, Poole EMCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyAssociation of Ovarian Tumor ?2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1587-1594.Cancer Epidemiol Biomarkers Prev2016-09-01T00:00:002016Association of Ovarian Tumor ?2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival.27742688Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein GCancer researchUbiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. 2016 12 15; 76(24):7194-7207.Cancer Res2016-10-14T00:00:002016Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.27823375Kendricks AL, Pageon LR, Craig SL, Wen Y, Sood AK, Lockworth CRJournal of the American Veterinary Medical AssociationPathology in Practice. J Am Vet Med Assoc. 2016 Nov 15; 249(10):1149-1151.J Am Vet Med Assoc2016-11-15T00:00:002016Pathology in Practice.27890659Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, Guo PNanomedicine : nanotechnology, biology, and medicineRNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine. 2017 04; 13(3):1183-1193.Nanomedicine2016-11-25T00:00:002016RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.27992857Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov ASAgingTFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519.Aging (Albany NY)2016-12-16T00:00:002016TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin.27720213Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GAEBioMedicinemicroRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine. 2016 Oct; 12:34-42.EBioMedicine2016-09-20T00:00:002016microRNA Therapeutics in Cancer - An Emerging Concept.27741356Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, Hamilton SR, Sun B, Zhang WThe Journal of pathologyMIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. J Pathol. 2017 Jan; 241(1):67-79.J Pathol2016-11-24T00:00:002016MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer.27803105Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang RCancer researchBET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res. 2016 11 01; 76(21):6320-6330.Cancer Res2016-11-01T00:00:002016BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.27806300Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AKCell reportsRole of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep. 2016 11 01; 17(6):1621-1631.Cell Rep2016-11-01T00:00:002016Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.28057718Gangwar R, Meena AS, Shukla PK, Nagaraja AS, Dorniak PL, Pallikuth S, Waters CM, Sood A, Rao RThe Biochemical journalCalcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress. Biochem J. 2017 02 20; 474(5):731-749.Biochem J2017-02-20T00:00:002017Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress.28131526Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DMGynecologic oncologyRole of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecol Oncol. 2017 03; 144(3):496-502.Gynecol Oncol2017-01-26T00:00:002017Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.28265009Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AKMolecular cancer therapeuticsPreclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123.Mol Cancer Ther2017-03-06T00:00:002017Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).27777972Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AKJCI insightImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016 Oct 20; 1(17):e87754.JCI Insight2016-10-20T00:00:002016Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.27843314Han HD, Byeon Y, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YMInternational journal of nanomedicineToll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine. 2016; 11:5729-5742.Int J Nanomedicine2016-11-02T00:00:002016Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.27547777Whiting N, Hu J, Zacharias NM, Lokesh GL, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya PJournal of medical imaging (Bellingham, Wash.)Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. J Med Imaging (Bellingham). 2016 Jul; 3(3):036001.J Med Imaging (Bellingham)2016-08-10T00:00:002016Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer.27612280Barata P, Sood AK, Hong DSCancer treatment reviewsRNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016 Nov; 50:35-47.Cancer Treat Rev2016-08-28T00:00:002016RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.27760566Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang WJournal of hematology & oncologyMIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2016 10 19; 9(1):112.J Hematol Oncol2016-10-19T00:00:002016MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis.27828713Previs RA, Sood AK, Mills GB, Westin SNExpert review of molecular diagnosticsThe rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1337-1351.Expert Rev Mol Diagn2016-12-01T00:00:002016The rise of genomic profiling in ovarian cancer.27839510Wang H, Li X, Volk DE, Lokesh GL, Elizondo-Riojas MA, Li L, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DGBioTechniquesMorph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery. Biotechniques. 2016; 61(5):249-259.Biotechniques2016-11-01T00:00:002016Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.27903673Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GAClinical cancer research : an official journal of the American Association for Cancer ResearchCombining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904.Clin Cancer Res2016-11-30T00:00:002016Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.27903842Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood A, Yang P, Yeung SJIntegrative cancer therapiesA Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integr Cancer Ther. 2017 03; 16(1):3-20.Integr Cancer Ther2016-11-30T00:00:002016A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience.27910914Han HD, Byeon Y, Jang JH, Jeon HN, Kim GH, Kim MG, Pack CG, Kang TH, Jung ID, Lim YT, Lee YJ, Lee JW, Shin BC, Ahn HJ, Sood AK, Park YMScientific reportsIn vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep. 2016 12 02; 6:38348.Sci Rep2016-12-02T00:00:002016In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.28097239Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi IJCI insightMetastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419.JCI Insight2017-01-12T00:00:002017Metastasis regulation by PPARD expression in cancer cells.28223424Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodr?guez-Aguayo C, L?pez-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo MMolecular cancer therapeuticsHSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Mol Cancer Ther. 2017 05; 16(5):966-976.Mol Cancer Ther2017-02-21T00:00:002017HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer.28376174Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AKJournal of the National Cancer InstituteRole of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).J Natl Cancer Inst2017-07-01T00:00:002017Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.28611202Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan VClinical cancer research : an official journal of the American Association for Cancer ResearchRole of Platelet-Derived Tgf?1 in the Progression of Ovarian Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5611-5621.Clin Cancer Res2017-06-13T00:00:002017Role of Platelet-Derived Tgf?1 in the Progression of Ovarian Cancer.28620240Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic PScientific reportsmiR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Sci Rep. 2017 06 15; 7(1):3614.Sci Rep2017-06-15T00:00:002017miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.28306624Trudel-Fitzgerald C, Poole EM, Idahl A, Lundin E, Sood AK, Kawachi I, Kubzansky LD, Tworoger SSPsychosomatic medicineThe Association of Work Characteristics With Ovarian Cancer Risk and Mortality. Psychosom Med. 2017 Nov/Dec; 79(9):1059-1067.Psychosom Med2017-11-01T00:00:002017The Association of Work Characteristics With Ovarian Cancer Risk and Mortality.28315702Kumar MNVR, Sood AKCancer lettersEditorial - Metronomic chemotherapy. Cancer Lett. 2017 08 01; 400:203.Cancer Lett2017-03-16T00:00:002017Editorial - Metronomic chemotherapy.28416487Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LSCancer researchMetabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res. 2017 06 01; 77(11):2903-2913.Cancer Res2017-04-17T00:00:002017Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.28423620Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GLOncotargetExosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 2017 Mar 21; 8(12):20145-20164.Oncotarget2017-03-21T00:00:002017Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.28423708Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli SOncotargetTargeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 2017 Apr 18; 8(16):27380-27392.Oncotarget2017-04-18T00:00:002017Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.28527672Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AKGynecologic oncologyQuality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecol Oncol. 2017 07; 146(1):101-108.Gynecol Oncol2017-05-17T00:00:002017Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.28725457Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill SM, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukherjee S, Mills GB, Ram PTNPJ systems biology and applicationsGenome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. NPJ Syst Biol Appl. 2015; 1:15001.NPJ Syst Biol Appl2015-09-28T00:00:002015Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers.28730442Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Chitosan Nanoparticles for miRNA Delivery. Methods Mol Biol. 2017; 1632:219-230.Methods Mol Biol2017-01-01T00:00:002017Chitosan Nanoparticles for miRNA Delivery.28730545Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KVCancer metastasis reviewsPlatelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017 06; 36(2):199-213.Cancer Metastasis Rev2017-06-01T00:00:002017Platelet "first responders" in wound response, cancer, and metastasis.28452421Sreedharanunni S, Varma N, Sachdeva MUS, Naseem S, Malhotra P, Bansal D, Sood A, Bose P, Varma SEuropean journal of haematologyParoxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes. Eur J Haematol. 2017 08; 99(2):194-195.Eur J Haematol2017-08-01T00:00:002017Paroxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes.28679740Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan VBloodRole of ADP receptors on platelets in the growth of ovarian cancer. Blood. 2017 09 07; 130(10):1235-1242.Blood2017-07-05T00:00:002017Role of ADP receptors on platelets in the growth of ovarian cancer.28855350Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchMacrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.Clin Cancer Res2017-08-29T00:00:002017Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.28985752Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang WJournal of hematology & oncologyErratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol. 2017 10 06; 10(1):163.J Hematol Oncol2017-10-06T00:00:002017Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis.29132875Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TMGynecologic oncologyAspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018 01; 148(1):222-232.Gynecol Oncol2017-11-11T00:00:002017Aspirin use and endometrial cancer risk and survival.28787528Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DMJournal of surgical oncologyImpact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb; 117(2):236-244.J Surg Oncol2017-08-08T00:00:002017Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.28928826Pu T, Xiong L, Liu Q, Zhang M, Cai Q, Liu H, Sood AK, Li G, Kang Y, Xu COncology lettersDelineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. Oncol Lett. 2017 Sep; 14(3):2869-2877.Oncol Lett2017-07-05T00:00:002017Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging.28978180Chung JF, Lee SJ, Sood AKOncotargetImmunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget. 2017 Sep 15; 8(40):69047-69061.Oncotarget2017-05-10T00:00:002017Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment.29054012Hu X, Sood AK, Dang CV, Zhang LCurrent opinion in genetics & developmentThe role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev. 2018 02; 48:8-15.Curr Opin Genet Dev2017-10-17T00:00:002017The role of long noncoding RNAs in cancer: the dark matter matters.29112229Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SWCancerBiobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer. 2018 02 01; 124(3):580-586.Cancer2017-11-07T00:00:002017Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.29118262Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JVScience translational medicineStress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ?-blockers. Sci Transl Med. 2017 Nov 08; 9(415).Sci Transl Med2017-11-08T00:00:002017Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ?-blockers.29179445Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang WOncotargetADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget. 2017 Oct 24; 8(51):88410-88420.Oncotarget2016-08-08T00:00:002016ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy.29180229Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov ASMolecular and cellular neurosciencesPeroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci. 2018 01; 86:65-71.Mol Cell Neurosci2017-11-24T00:00:002017Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy.29180471Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CVCancer researchMYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res. 2018 01 01; 78(1):64-74.Cancer Res2017-11-27T00:00:002017MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.29185273Matsuo K, Machida H, Grubbs BH, Sood AK, Gershenson DMJournal of gynecologic oncologyTrends of low-grade serous ovarian carcinoma in the United States. J Gynecol Oncol. 2018 01; 29(1):e15.J Gynecol Oncol2018-01-01T00:00:002018Trends of low-grade serous ovarian carcinoma in the United States.29237804Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AKMolecular cancer therapeuticsInhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.Mol Cancer Ther2017-12-13T00:00:002017Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.29242937Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian CJAMA oncologyPaclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.JAMA Oncol2018-02-01T00:00:002018Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.29246304Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein GMolecular therapy. Nucleic acidsTherapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids. 2017 Dec 15; 9:251-262.Mol Ther Nucleic Acids2017-07-05T00:00:002017Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.28711723Cuneo MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SKPsychoneuroendocrinologyDiurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology. 2017 Oct; 84:139-142.Psychoneuroendocrinology2017-06-30T00:00:002017Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer.28827520Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AKNature communicationsPlatelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017 08 21; 8(1):310.Nat Commun2017-08-21T00:00:002017Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.28904816Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein GCell discoveryRegulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2017; 3:17029.Cell Discov2017-09-12T00:00:002017Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.28637314Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W, Chen KCarcinogenesisDNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis. 2017 08 01; 38(8):797-805.Carcinogenesis2017-08-01T00:00:002017DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.28814667Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AKJCI insightAdrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16).JCI Insight2017-08-17T00:00:002017Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.29251630Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SCThe Journal of clinical investigationCancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018 02 01; 128(2):589-606.J Clin Invest2017-12-18T00:00:002017Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.29396402Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AANature communicationsTuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2018 02 02; 9(1):476.Nat Commun2018-02-02T00:00:002018Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.29398795Tahlan A, Varma N, Naseem S, Bansal D, Binota J, Sood A, Sachdeva MUS, Malhotra P, Varma SIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionComparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults. Indian J Hematol Blood Transfus. 2018 Jan; 34(1):19-24.Indian J Hematol Blood Transfus2017-05-09T00:00:002017Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults.29386184Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DNCancer researchLPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res. 2018 04 15; 78(8):1923-1934.Cancer Res2018-01-31T00:00:002018LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.29386624Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, Bar-Eli MNature communicationsA-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun. 2018 01 31; 9(1):461.Nat Commun2018-01-31T00:00:002018A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.29388135Filant J, Nejad P, Paul A, Simonson B, Srinivasan S, Zhang X, Balaj L, Das S, Gandhi R, Laurent LC, Sood AKMethods in molecular biology (Clifton, N.J.)Isolation of Extracellular RNA from Serum/Plasma. Methods Mol Biol. 2018; 1740:43-57.Methods Mol Biol2018-01-01T00:00:002018Isolation of Extracellular RNA from Serum/Plasma.29456965Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AKFrontiers in oncologyCorrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2018; 8:9.Front Oncol2018-02-09T00:00:002018Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.29594152Vu HT, Kotla S, Ko KA, Fujii Y, Tao Y, Medina J, Thomas T, Hada M, Sood AK, Singh PK, Milgrom SA, Krishnan S, Fujiwara K, Le NT, Abe JIFrontiers in cardiovascular medicineIonizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. Front Cardiovasc Med. 2018; 5:23.Front Cardiovasc Med2018-03-14T00:00:002018Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation.29809169Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AKThe Journal of clinical investigationATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2018 07 02; 128(7):3199.J Clin Invest2018-05-29T00:00:002018ATP11B mediates platinum resistance in ovarian cancer.29228548Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AKOncotargetMacrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.Oncotarget2017-08-24T00:00:002017Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.29657130Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AKCancer cellThe Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. 2018 06 11; 33(6):965-983.Cancer Cell2018-04-12T00:00:002018The Platelet Lifeline to Cancer: Challenges and Opportunities.29661830Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AKCancer researchSustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 06 15; 78(12):3233-3242.Cancer Res2018-04-16T00:00:002018Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.29212026Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AKCell reportsDifferential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.Cell Rep2017-12-05T00:00:002017Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.29553098Liu Q, Lu C, Dai W, Li K, Xu J, Huang Y, Li G, Kang Y, Sood AK, Xu CBioscience trendsAssociation of biobehavioral factors with non-coding RNAs in cervical cancer. Biosci Trends. 2018; 12(1):24-31.Biosci Trends2018-01-01T00:00:002018Association of biobehavioral factors with non-coding RNAs in cervical cancer.29560266Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood AF1000ResearchThe role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res. 2018; 7:326.F1000Res2018-03-15T00:00:002018The role of tumor microenvironment in resistance to anti-angiogenic therapy.29861415Bullock MD, Silva AM, Kanlikilicer-Unaldi P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GANon-coding RNAExosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Noncoding RNA. 2015 Jun 03; 1(1):53-68.Noncoding RNA2015-06-03T00:00:002015Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer.29861857Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AKOncotargetADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126.Oncotarget2018-05-18T00:00:002018ADH1B promotes mesothelial clearance and ovarian cancer infiltration.30012564Gonz?lez-Gonz?lez A, Mu?oz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jim?nez G, Verma A, Ram?rez A, Qian W, Chen W, Kozielski AJ, Elemento O, Mart?n-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, Garc?a MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, S?nchez-Rovira P, Chang JC, Granados-Principal SClinical cancer research : an official journal of the American Association for Cancer ResearchActivating Transcription Factor 4 Modulates TGF?-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res. 2018 11 15; 24(22):5697-5709.Clin Cancer Res2018-07-16T00:00:002018Activating Transcription Factor 4 Modulates TGF?-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.30084832Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RCClinical cancer research : an official journal of the American Association for Cancer ResearchPaclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2018 10 15; 24(20):5072-5084.Clin Cancer Res2018-07-03T00:00:002018Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.30213435Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SNGynecologic oncologyA practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.Gynecol Oncol2018-09-10T00:00:002018A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.29905941Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SKCancerLife stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer. 2018 08; 124(16):3401-3408.Cancer2018-06-15T00:00:002018Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.30396690Salcedo MP, Sood AK, Dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Ramirez PT, Schmeler KMGynecologic oncologyPerineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecol Oncol. 2019 01; 152(1):101-105.Gynecol Oncol2018-11-03T00:00:002018Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.29800703Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu SBrain, behavior, and immunityPerioperative inhibition of ?-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain Behav Immun. 2018 10; 73:294-309.Brain Behav Immun2018-05-22T00:00:002018Perioperative inhibition of ?-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.29889660Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AKJCI insightAdrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2018 Jun 07; 3(11).JCI Insight2018-06-07T00:00:002018Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.29889661Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AKJCI insightImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2018 06 07; 3(11).JCI Insight2018-06-07T00:00:002018Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.29890852Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, Park YMDrug deliverySelective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Deliv. 2018 Nov; 25(1):1394-1402.Drug Deliv2018-11-01T00:00:002018Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.29959278Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AKThe Journal of biological chemistryStress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2018 06 29; 293(26):10041.J Biol Chem2018-06-29T00:00:002018Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.29977351Dal Molin GZ, Omatsu K, Sood AK, Coleman RLTherapeutic advances in medical oncologyRucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol. 2018; 10:1758835918778483.Ther Adv Med Oncol2018-06-22T00:00:002018Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.30036226Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AKInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyWhen Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490.Int J Gynecol Cancer2018-10-01T00:00:002018When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.30046746Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, L?pez JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler HResearch and practice in thrombosis and haemostasisAdvances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Res Pract Thromb Haemost. 2018 Jul; 2(3):407-428.Res Pract Thromb Haemost2018-04-12T00:00:002018Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.30050129Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AKNature communicationsFABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923.Nat Commun2018-07-26T00:00:002018FABP4 as a key determinant of metastatic potential of ovarian cancer.30115698Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YMCancer researchCD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. Cancer Res. 2018 11 01; 78(21):6247-6256.Cancer Res2018-08-16T00:00:002018CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.30181330Zhang L, Peng D, Sood AK, Dang CV, Zhong XMolecular cancer therapeuticsShedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Mol Cancer Ther. 2018 09; 17(9):1816-1823.Mol Cancer Ther2018-09-01T00:00:002018Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer.29872699Wagner MJ, Ravi V, Menter DG, Sood AKNPJ precision oncologyEndothelial cell malignancies: new insights from the laboratory and clinic. NPJ Precis Oncol. 2017; 1(1):11.NPJ Precis Oncol2017-04-20T00:00:002017Endothelial cell malignancies: new insights from the laboratory and clinic.29872708Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AKNPJ precision oncologyImmune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017; 1(1):26.NPJ Precis Oncol2017-08-15T00:00:002017Immune cell profiling in cancer: molecular approaches to cell-specific identification.30095787Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AKObstetrics and gynecologyLaparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.Obstet Gynecol2018-09-01T00:00:002018Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.30655206Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein GEBioMedicinePTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 2019 Feb; 40:290-304.EBioMedicine2019-01-14T00:00:002019PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.30487062Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein GEBioMedicineExosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018 Dec; 38:100-112.EBioMedicine2018-11-25T00:00:002018Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.30503552Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DNCancer lettersOvarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett. 2019 02 01; 442:464-474.Cancer Lett2018-11-29T00:00:002018Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.30291236Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao BNature communicationsBone protection by inhibition of microRNA-182. Nat Commun. 2018 10 05; 9(1):4108.Nat Commun2018-10-05T00:00:002018Bone protection by inhibition of microRNA-182.30300578Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang LCancer cellIntegrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 2018 10 08; 34(4):549-560.e9.Cancer Cell2018-10-08T00:00:002018Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.30305341Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AKMolecular cancer therapeuticsPRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.Mol Cancer Ther2018-10-10T00:00:002018PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.30366647Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming NDGynecologic oncologyConcordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432.Gynecol Oncol2018-10-23T00:00:002018Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.30369761Sharma S, Sharma P, Sachdeva MUS, Binota J, Sood A, Malhotra P, Varma NIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionCirculating Mature Megakaryocytes in an Unusual Case of BCR-ABL1-Positive CML. Indian J Hematol Blood Transfus. 2018 Oct; 34(4):762-764.Indian J Hematol Blood Transfus2018-06-26T00:00:002018Circulating Mature Megakaryocytes in an Unusual Case of BCR-ABL1-Positive CML.30455428An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang NOncogeneEGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. 2019 03; 38(12):2123-2134.Oncogene2018-11-19T00:00:002018EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.30614472LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RLThe Lancet. OncologyExploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 01; 20(1):e15-e28.Lancet Oncol2019-01-01T00:00:002019Exploring and comparing adverse events between PARP inhibitors.Authorship 9416583Authorship 9419313Authorship 9419759Authorship 9422266Authorship 942637630770374Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LSClinical chemistryPerformance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clin Chem. 2019 05; 65(5):674-683.Clin Chem2019-02-15T00:00:002019Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer.30835824Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou LCancerCritical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972.Cancer2019-03-05T00:00:002019Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.29243000Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AKCancer metastasis reviewsRNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018 03; 37(1):107-124.Cancer Metastasis Rev2018-03-01T00:00:002018RNA interference-based therapy and its delivery systems.30797590Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DMGynecologic oncologyMucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecol Oncol. 2019 05; 153(2):230-237.Gynecol Oncol2019-02-20T00:00:002019Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.30861414Bach DH, Lee SK, Sood AKMolecular therapy. Nucleic acidsCircular RNAs in Cancer. Mol Ther Nucleic Acids. 2019 Jun 07; 16:118-129.Mol Ther Nucleic Acids2019-02-16T00:00:002019Circular RNAs in Cancer.Authorship 94300813Authorship 9435661630918328Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CVOncogeneQuaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. 2019 06; 38(26):5191-5210.Oncogene2019-03-27T00:00:002019Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.30926640Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AKMolecular cancer therapeuticsGnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.Mol Cancer Ther2019-03-29T00:00:002019GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.Authorship 9438325Authorship 94390219Authorship 9439936Authorship 944239530112590Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DGCancer metastasis reviewsBioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. 2018 09; 37(2-3):439-454.Cancer Metastasis Rev2018-09-01T00:00:002018Bioactive lipid metabolism in platelet "first responder" and cancer biology.30420565Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AKMolecular cancer therapeuticsPredicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther. 2019 02; 18(2):421-436.Mol Cancer Ther2018-11-12T00:00:002018Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.29860375Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KAJAMA oncologyDefining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 11 01; 4(11):1519-1526.JAMA Oncol2018-11-01T00:00:002018Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach.29948328Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AKCancer metastasis reviewsStress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev. 2018 09; 37(2-3):203-211.Cancer Metastasis Rev2018-09-01T00:00:002018Stress, inflammation, and eicosanoids: an emerging perspective.Authorship 94493241Authorship 9450833130951671Srinivasan S, Yeri A, Cheah PS, Chung A, Danielson K, De Hoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Murthy VL, Nejad P, Paul A, Rigoutsos I, Rodosthenous R, Shah RV, Simonson B, To C, Wong D, Yan IK, Zhang X, Balaj L, Breakefield XO, Daaboul G, Gandhi R, Lapidus J, Londin E, Patel T, Raffai RL, Sood AK, Alexander RP, Das S, Laurent LCCellSmall RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell. 2019 04 04; 177(2):446-462.e16.Cell2019-04-04T00:00:002019Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation.30951672Murillo OD, Thistlethwaite W, Rozowsky J, Subramanian SL, Lucero R, Shah N, Jackson AR, Srinivasan S, Chung A, Laurent CD, Kitchen RR, Galeev T, Warrell J, Diao JA, Welsh JA, Hanspers K, Riutta A, Burgstaller-Muehlbacher S, Shah RV, Yeri A, Jenkins LM, Ahsen ME, Cordon-Cardo C, Dogra N, Gifford SM, Smith JT, Stolovitzky G, Tewari AK, Wunsch BH, Yadav KK, Danielson KM, Filant J, Moeller C, Nejad P, Paul A, Simonson B, Wong DK, Zhang X, Balaj L, Gandhi R, Sood AK, Alexander RP, Wang L, Wu C, Wong DTW, Galas DJ, Van Keuren-Jensen K, Patel T, Jones JC, Das S, Cheung KH, Pico AR, Su AI, Raffai RL, Laurent LC, Roth ME, Gerstein MB, Milosavljevic ACellexRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. Cell. 2019 04 04; 177(2):463-477.e15.Cell2019-04-04T00:00:002019exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids.Authorship 94556612Authorship 94584916Authorship 945894231012964Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EHCancerActivating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. 2019 07 15; 125(14):2409-2422.Cancer2019-04-23T00:00:002019Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.31005045Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJPsychoneuroendocrinologyOxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology. 2019 08; 106:244-251.Psychoneuroendocrinology2019-04-06T00:00:002019Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.31024931Abe JI, Sood AK, Martin JFFrontiers in cardiovascular medicineEditorial: Cardio-Oncology: From Bench to Bedside. Front Cardiovasc Med. 2019; 6:37.Front Cardiovasc Med2019-04-10T00:00:002019Editorial: Cardio-Oncology: From Bench to Bedside.Authorship 9466719Authorship 9468821231056473McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AKEBioMedicinePan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine. 2019 May; 43:127-137.EBioMedicine2019-05-02T00:00:002019Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.31063534Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JSCarcinogenesisCorrigendum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2019 Jul 20; 40(7):936.Carcinogenesis2019-07-20T00:00:002019Corrigendum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.23669443Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu JInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyCA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Jun; 23(5):815-22.Int J Gynecol Cancer2013-06-01T00:00:002013CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.Authorship 94735815Authorship 94759811Authorship 947717731092618Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchCorrection: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin Cancer Res. 2019 May 15; 25(10):3194.Clin Cancer Res2019-05-15T00:00:002019Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.31126961Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJClinical cancer research : an official journal of the American Association for Cancer ResearchAdvancing Drug Development in Gynecologic Malignancies. Clin Cancer Res. 2019 08 15; 25(16):4874-4880.Clin Cancer Res2019-05-24T00:00:002019Advancing Drug Development in Gynecologic Malignancies.31127195Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YNatureAuthor Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2019 Jun; 570(7761):E51.Nature2019-06-01T00:00:002019Author Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Authorship 9490381331191824Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SNOncotargetAdaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.Oncotarget2019-05-28T00:00:002019Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.Authorship 9515991731289363Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AKOncogeneIdentifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. 2019 08; 38(33):6095-6108.Oncogene2019-07-09T00:00:002019Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.Authorship 952695331350294Bach DH, Zhang W, Sood AKCancer researchChromosomal Instability in Tumor Initiation and Development. Cancer Res. 2019 08 15; 79(16):3995-4002.Cancer Res2019-07-26T00:00:002019Chromosomal Instability in Tumor Initiation and Development.Authorship 95283916Authorship 9530413Authorship 9531322031371750Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell GL, Conrads T, Sood AK, Orr D, Holmes LM, Gevaert M, Crosswell HE, DesRochers TMScientific reportsProspective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. Sci Rep. 2019 08 01; 9(1):11153.Sci Rep2019-08-01T00:00:002019Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.31353053Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AKGynecologic oncologyProspective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530.Gynecol Oncol2019-07-25T00:00:002019Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.31365748Chelariu-Raicu A, Coleman RL, Sood AKOncology (Williston Park, N.Y.)Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park). 2019 07 16; 33(7).Oncology (Williston Park)2019-07-16T00:00:002019Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?Authorship 9534782031391192Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu ZClinical cancer research : an official journal of the American Association for Cancer Research6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res. 2019 09 15; 25(18):5702-5716.Clin Cancer Res2019-08-07T00:00:0020196-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.Authorship 9542991331439676Han C, Wang C, Chen Y, Wang J, Xu X, Hilton T, Cai W, Zhao Z, Wu Y, Li K, Houck K, Liu L, Sood AK, Wu X, Xue F, Li M, Dong JF, Zhang JHaematologicaPlacenta-derived extracellular vesicles induce preeclampsia in mouse models. Haematologica. 2020 06; 105(6):1686-1694.Haematologica2019-08-22T00:00:002019Placenta-derived extracellular vesicles induce preeclampsia in mouse models.Authorship 9561511031560538Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li CBioconjugate chemistryCopper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. Bioconjug Chem. 2019 10 16; 30(10):2675-2683.Bioconjug Chem2019-09-27T00:00:002019Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention.Authorship 956868331592935Trudel-Fitzgerald C, Poole EM, Sood AK, Okereke OI, Kawachi I, Kubzansky LD, Tworoger SSPsychosomatic medicineSocial Integration, Marital Status, and Ovarian Cancer Risk: A 20-Year Prospective Cohort Study. Psychosom Med. 2019 Nov/Dec; 81(9):833-840.Psychosom Med2019-11-01T00:00:002019Social Integration, Marital Status, and Ovarian Cancer Risk: A 20-Year Prospective Cohort Study.Authorship 9576961331640461Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AKCancer biology & therapyClinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther. 2020; 21(2):147-156.Cancer Biol Ther2019-10-22T00:00:002019Clinical and biological significance of EZH2 expression in endometrial cancer.Authorship 958219231672769Handley KF, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchA Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer. Clin Cancer Res. 2020 01 01; 26(1):9-10.Clin Cancer Res2019-10-31T00:00:002019A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer.Authorship 9604701231682236Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang HThe Journal of clinical investigationA-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest. 2019 12 02; 129(12):5343-5356.J Clin Invest2019-12-02T00:00:002019A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.Authorship 9611051231730714Lara OD, Wang Y, Asare A, Xu T, Chiu HS, Liu Y, Hu W, Sumazin P, Uppal S, Zhang L, Rauh-Hain JA, Sood AKCancerPan-cancer clinical and molecular analysis of racial disparities. Cancer. 2020 02 15; 126(4):800-807.Cancer2019-11-15T00:00:002019Pan-cancer clinical and molecular analysis of racial disparities.Authorship 9615866Authorship 96165830Authorship 9616731731764736Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, Gershenson DM, Schmeler KM, Malpica A, Fader AN, Frumovitz MObstetrics and gynecologyEffects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstet Gynecol. 2019 12; 134(6):1253-1259.Obstet Gynecol2019-12-01T00:00:002019Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.31771620Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JWGenome biologyPharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biol. 2019 11 26; 20(1):253.Genome Biol2019-11-26T00:00:002019Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.31772388Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AKScientific reportsTumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589.Sci Rep2019-11-26T00:00:002019Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.Authorship 9620991431799396Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AKScience advancesMechanisms of nuclear content loading to exosomes. Sci Adv. 2019 11; 5(11):eaax8849.Sci Adv2019-11-20T00:00:002019Mechanisms of nuclear content loading to exosomes.Authorship 9626398Authorship 962746531839342Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SSGynecologic oncologyPredictors of survival trajectories among women with epithelial ovarian cancer. Gynecol Oncol. 2020 02; 156(2):459-466.Gynecol Oncol2019-12-12T00:00:002019Predictors of survival trajectories among women with epithelial ovarian cancer.31847695Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein GRNA biologyLong non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biol. 2020 11; 17(11):1523-1534.RNA Biol2019-12-17T00:00:002019Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.Authorship 97467919Authorship 974751231875548Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan PCell reportsmiRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep. 2019 12 24; 29(13):4389-4406.e10.Cell Rep2019-12-24T00:00:002019miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.31881262Seiler A, Sood AK, Jenewein J, Fagundes CPBrain, behavior, and immunityCan stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms. Brain Behav Immun. 2020 07; 87:860-880.Brain Behav Immun2019-12-24T00:00:002019Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms.Authorship 97575312Authorship 9759581231949258Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li CScientific reportsTargeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Sci Rep. 2020 01 16; 10(1):520.Sci Rep2020-01-16T00:00:002020Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.31935430El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein GCellular signallingGATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 04; 68:109539.Cell Signal2020-01-11T00:00:002020GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.Authorship 9760777Authorship 9760787Authorship 97621014Authorship 9762511931972470Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein GEBioMedicineCorrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. EBioMedicine. 2020 Feb; 52:102630.EBioMedicine2020-01-20T00:00:002020Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112].31954534Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JDGynecologic oncologyEvolving population-based statistics for rare epithelial ovarian cancers. Gynecol Oncol. 2020 04; 157(1):3-11.Gynecol Oncol2020-01-15T00:00:002020Evolving population-based statistics for rare epithelial ovarian cancers.31954535Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DMGynecologic oncologyDiagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecol Oncol. 2020 04; 157(1):21-28.Gynecol Oncol2020-01-15T00:00:002020Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.31969252Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fern?ndez ML, Ray-Coquard I, Gershenson DMGynecologic oncologyLow-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725.Gynecol Oncol2020-01-20T00:00:002020Low-grade serous ovarian cancer: State of the science.Authorship 9777265Authorship 9779561532037195Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KNGynecologic oncologyDemcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecol Oncol. 2020 05; 157(2):386-391.Gynecol Oncol2020-02-07T00:00:002020Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.32059873Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnica-Worms D, Peng W, Zhou D, Sood AK, Li CNanomedicine : nanotechnology, biology, and medicineInduction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine. 2020 04; 25:102169.Nanomedicine2020-02-12T00:00:002020Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition.Authorship 979709232125711Salcedo MP, Sood AK, Jhingran A, Eifel PJ, Klopp AH, Iyer RB, Fellman BM, Jimenez C, Schmeler KMCancerPelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer. 2020 06 01; 126(11):2607-2613.Cancer2020-03-03T00:00:002020Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women.Authorship 986584832252881Wi TI, Byeon Y, Won JE, Lee JM, Kang TH, Lee JW, Lee YJ, Sood AK, Han HD, Park YMJournal of biomedical nanotechnologySelective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy. J Biomed Nanotechnol. 2020 Feb 01; 16(2):201-211.J Biomed Nanotechnol2020-02-01T00:00:002020Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy.Authorship 98741446Authorship 987626632294438Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AKCell reportsMolecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.Cell Rep2020-04-14T00:00:002020Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.32303888Nusbaum DJ, Mandelbaum RS, Machida H, Matsuzaki S, Roman LD, Sood AK, Gershenson DM, Matsuo KArchives of gynecology and obstetricsSignificance of lymph node ratio on survival of women with borderline ovarian tumors. Arch Gynecol Obstet. 2020 05; 301(5):1289-1298.Arch Gynecol Obstet2020-04-17T00:00:002020Significance of lymph node ratio on survival of women with borderline ovarian tumors.Authorship 988925532384350Cata JP, Gorur A, Yuan X, Berg NK, Sood AK, Eltzschig HKAnesthesia and analgesiaRole of Micro-RNA for Pain After Surgery: Narrative Review of Animal and Human Studies. Anesth Analg. 2020 06; 130(6):1638-1652.Anesth Analg2020-06-01T00:00:002020Role of Micro-RNA for Pain After Surgery: Narrative Review of Animal and Human Studies.Authorship 989385932402635Matsuo K, Chang EJ, Matsuzaki S, Mandelbaum RS, Matsushima K, Grubbs BH, Klar M, Roman LD, Sood AK, Wright JDGynecologic oncologyMinimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. Gynecol Oncol. 2020 07; 158(1):59-65.Gynecol Oncol2020-05-10T00:00:002020Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.Authorship 99082811Authorship 9908857Authorship 99095029Authorship 9910301132493919Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AKNature communicationsAuthor Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2020 06 03; 11(1):2867.Nat Commun2020-06-03T00:00:002020Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.32499298Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AKMolecular cancer therapeuticsNRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735.Mol Cancer Ther2020-06-04T00:00:002020NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.32483375Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YNatureRetraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2020 06; 582(7810):134.Nature2020-06-01T00:00:002020Retraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.32485873Maoz A, Matsuo K, Ciccone MA, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DMCancersMolecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review. Cancers (Basel). 2020 May 29; 12(6).Cancers (Basel)2020-05-29T00:00:002020Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review.Authorship 991563632525512Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, Wright JDJAMA oncologyMinimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. JAMA Oncol. 2020 07 01; 6(7):1110-1113.JAMA Oncol2020-07-01T00:00:002020Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer.Authorship 9936071732623336Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, Lutgendorf SK, Sood AKiScienceSustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. iScience. 2020 Jul 24; 23(7):101289.iScience2020-06-20T00:00:002020Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells.Authorship 9949628Authorship 99513120Authorship 9952007Authorship 9954926Authorship 9958271332709538Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DMGynecologic oncologyThe role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658.Gynecol Oncol2020-07-22T00:00:002020The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.32691853Lutgendorf SK, Penedo F, Goodheart MJ, Dahmoush L, Arevalo JMG, Thaker PH, Slavich GM, Sood AK, Cole SWCancerEpithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer. 2020 10 01; 126(19):4407-4413.Cancer2020-07-21T00:00:002020Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.32702466Liu Y, Wu S, Koo Y, Yang A, Dai Y, Khant H, Osman SR, Chowdhury M, Wei H, Li Y, Court K, Hwang E, Wen Y, Dasari SK, Nguyen M, Tang EC, Chehab EW, de Val N, Braam J, Sood AKNanomedicine : nanotechnology, biology, and medicineCharacterization of and isolation methods for plant leaf nanovesicles and small extracellular vesicles. Nanomedicine. 2020 10; 29:102271.Nanomedicine2020-07-21T00:00:002020Characterization of and isolation methods for plant leaf nanovesicles and small extracellular vesicles.32717032Saha B, Mathur T, Handley KF, Hu W, Afshar-Kharghan V, Sood AK, Jain ABlood advancesOvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. Blood Adv. 2020 07 28; 4(14):3329-3342.Blood Adv2020-07-28T00:00:002020OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer.32737156Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly K, Sood AKMolecular cancer therapeuticsBlockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer. Mol Cancer Ther. 2020 09; 19(9):1943-1954.Mol Cancer Ther2020-07-31T00:00:002020Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer.Authorship 9961181432754300Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AKOncotargetTherapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget. 2020 Jul 21; 11(29):2819-2833.Oncotarget2020-07-21T00:00:002020Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.Authorship 997890232833387Cata JP, Sood AK, Eltzschig HKAnesthesiologyAnesthetic Drugs and Cancer Progression. Anesthesiology. 2020 10 01; 133(4):698-699.Anesthesiology2020-10-01T00:00:002020Anesthetic Drugs and Cancer Progression.Authorship 9989158Authorship 999640932943548Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AKMolecular cancer therapeuticsEnhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. Mol Cancer Ther. 2020 11; 19(11):2396-2406.Mol Cancer Ther2020-09-17T00:00:002020Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.32934031Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RCClinical cancer research : an official journal of the American Association for Cancer ResearchCorrection: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2020 09 15; 26(18):5050.Clin Cancer Res2020-09-15T00:00:002020Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.Authorship 10032758Authorship 10037731433087329Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Selvendiran K, Pei G, Zhao Z, Yoo JY, Kaur BClinical cancer research : an official journal of the American Association for Cancer ResearchOncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. Clin Cancer Res. 2021 01 15; 27(2):542-553.Clin Cancer Res2020-10-21T00:00:002020Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.33122243Bailey CD, Previs R, Fellman BM, Zaid T, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman P, Fleming ND, Nick A, Sood AK, Westin SNInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyPathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer. 2021 02; 31(2):232-237.Int J Gynecol Cancer2020-10-29T00:00:002020Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.Authorship 100448715Authorship 100456017Authorship 10049805Authorship 1005130833149280Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AKOncogeneThe hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.Oncogene2020-11-04T00:00:002020The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.33154095Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AKInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyCorrelation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.Int J Gynecol Cancer2020-11-05T00:00:002020Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.33183764Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo KGynecologic oncologyUterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021 02; 160(2):586-601.Gynecol Oncol2020-11-09T00:00:002020Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.33196436Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AKGynecologic oncologyPossible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecol Oncol. 2021 01; 160(1):32-39.Gynecol Oncol2020-10-24T00:00:002020Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.Authorship 10062171633262282Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fern?ndez FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC, Godwin AK, Miller KD, Cho CH, Kim JProceedings of the National Academy of Sciences of the United States of AmericaTargeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A. 2020 12 15; 117(50):31993-32004.Proc Natl Acad Sci U S A2020-12-01T00:00:002020Targeting progesterone signaling prevents metastatic ovarian cancer.Authorship 1008455433415580How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing AInvestigational new drugsThe clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.Invest New Drugs2021-01-07T00:00:002021The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.Authorship 10105408Authorship 1010583933536126Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LAGynecologic oncologyCost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.Gynecol Oncol2021-01-31T00:00:002021Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.33537658Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AKiScienceDistinct T?cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience. 2021 Feb 19; 24(2):102053.iScience2021-01-09T00:00:002021Distinct T?cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups.Authorship 101085417Authorship 10110085Authorship 101101620Authorship 101110417Authorship 10111801033567287Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AKCell reportsGain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021 02 09; 34(6):108726.Cell Rep2021-02-09T00:00:002021Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.33572451Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming NDCancersA Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4).Cancers (Basel)2021-02-09T00:00:002021A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy.33551196Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AKGynecologic oncologyDasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.Gynecol Oncol2021-02-04T00:00:002021Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.33562443Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming NDCancersEmerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers (Basel). 2021 Feb 05; 13(4).Cancers (Basel)2021-02-05T00:00:002021Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer.33563487Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AKGynecologic oncologyClinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.Gynecol Oncol2021-02-06T00:00:002021Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.Authorship 1012836933668685Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Zhang X, Ivan C, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo CInternational journal of molecular sciencesPRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. Int J Mol Sci. 2021 Feb 13; 22(4).Int J Mol Sci2021-02-13T00:00:002021PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.Authorship 1014478833760306Garvin L, Slavich GM, Schrepf A, Davis LZ, Thaker PH, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SKPsycho-oncologyChronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients. Psychooncology. 2021 06; 30(6):954-961.Psychooncology2021-04-01T00:00:002021Chronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients.Authorship 101507210Authorship 101562130Authorship 101565433Authorship 101565925Authorship 10157281933821990Cho MS, Li J, Gonzalez-Delgado R, Lee H, Vasquez M, He T, He Y, Liu K, Sasano T, N?rnberg B, Sood AK, Wong STC, Afshar-Kharghan VBlood advancesThe effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. Blood Adv. 2021 04 13; 5(7):1947-1951.Blood Adv2021-04-13T00:00:002021The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer.33792569Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AKThe Journal of clinical investigationATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2021 04 01; 131(7).J Clin Invest2021-04-01T00:00:002021ATP11B mediates platinum resistance in ovarian cancer.33793423Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AKJCI insightImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2021 04 08; 6(7).JCI Insight2021-04-08T00:00:002021Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.33793425Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AKJCI insightAdrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2021 04 08; 6(7).JCI Insight2021-04-08T00:00:002021Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.33795809Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton KL, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez-Paniagua M, Sahin AA, Rodriguez-Canales J, Gelovani J, Chang JT, Acharya G, Sood AK, Wistuba II, Gibbons DL, Solis LM, Barton MC, Varadarajan N, Rosen JM, Zhang XH, Mani SABritish journal of cancerCD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021 07; 125(2):176-189.Br J Cancer2021-04-01T00:00:002021CD8+ T cells inhibit metastasis and CXCL4 regulates its function.Authorship 10160951233838925Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AKGynecologic oncologyFactors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.Gynecol Oncol2021-04-07T00:00:002021Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.Authorship 10165575Authorship 1016832633887301Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu JHuman pathologyExpression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol. 2021 07; 113:20-27.Hum Pathol2021-04-19T00:00:002021Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.33867146Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JAGynecologic oncologyTiming of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2021 06; 161(3):660-667.Gynecol Oncol2021-04-16T00:00:002021Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.Authorship 101735510Authorship 10174171333927351Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Cheng W, Sood AK, Liu J, Gan BOncogeneFerroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene. 2021 05; 40(20):3533-3547.Oncogene2021-04-29T00:00:002021Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity.33931674Wagner MJ, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang WL, Ravi V, Holland EC, Sood AKScientific reportsCombined VEGFR and MAPK pathway inhibition in angiosarcoma. Sci Rep. 2021 04 30; 11(1):9362.Sci Rep2021-04-30T00:00:002021Combined VEGFR and MAPK pathway inhibition in angiosarcoma.Authorship 10184101733988982Amero P, Lokesh GLR, Chaudhari RR, Cardenas-Zuniga R, Schubert T, Attia YM, Montalvo-Gonzalez E, Elsayed AM, Ivan C, Wang Z, Cristini V, Franciscis V, Zhang S, Volk DE, Mitra R, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein GJournal of the American Chemical SocietyConversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. J Am Chem Soc. 2021 05 26; 143(20):7655-7670.J Am Chem Soc2021-05-14T00:00:002021Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity.Authorship 10193941234037709Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, Fujiwara K, Kim JW, K?bel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, Tworoger ST, Wentzensen N, Chanock SJ, Brennan P, Trabert BCarcinogenesisJoint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis. 2021 06 21; 42(6):785-793.Carcinogenesis2021-06-21T00:00:002021Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.Authorship 102008512Authorship 102018112Authorship 1020195734065218Gao C, Jin G, Forbes E, Mangala LS, Wang Y, Rodriguez-Aguayo C, Amero P, Bayraktar E, Yan Y, Lopez-Berestein G, Broaddus RR, Sood AK, Xue F, Zhang WCancersInactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy. Cancers (Basel). 2021 May 20; 13(10).Cancers (Basel)2021-05-20T00:00:002021Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy.34078919Bindra S, McGill MA, Triplett MK, Tyagi A, Thaker PH, Dahmoush L, Goodheart MJ, Ogden RT, Owusu-Ansah E, R Karan K, Cole S, Sood AK, Lutgendorf SK, Picard MScientific reportsMitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. Sci Rep. 2021 06 02; 11(1):11595.Sci Rep2021-06-02T00:00:002021Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors.34080583Cuneo MG, Szeto A, Schrepf A, Thaker PH, Goodheart M, Cole SW, Sood AK, McCabe PM, Mendez AJ, Lutgendorf SKPsychosomatic medicinePositive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment. Psychosom Med. 2021 06 01; 83(5):417-422.Psychosom Med2021-06-01T00:00:002021Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment.Authorship 1020522334090705Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JFGynecologic oncologyRationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol. 2021 08; 162(2):482-495.Gynecol Oncol2021-06-03T00:00:002021Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.Authorship 102559019Authorship 1025833934278265Hunt AL, Bateman NW, Barakat W, Makohon-Moore S, Hood BL, Conrads KA, Zhou M, Calvert V, Pierobon M, Loffredo J, Litzi TJ, Oliver J, Mitchell D, Gist G, Rojas C, Blanton B, Robinson EL, Odunsi K, Sood AK, Casablanca Y, Darcy KM, Shriver CD, Petricoin EF, Rao UNM, Maxwell GL, Conrads TPiScienceExtensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. iScience. 2021 Jul 23; 24(7):102757.iScience2021-06-21T00:00:002021Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.34290095Saha B, Mathur T, Tronolone JJ, Chokshi M, Lokhande GK, Selahi A, Gaharwar AK, Afshar-Kharghan V, Sood AK, Bao G, Jain AScience advancesHuman tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Sci Adv. 2021 07; 7(30).Sci Adv2021-07-21T00:00:002021Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer.Authorship 102674115Authorship 102709020Authorship 102709624Authorship 102709914Authorship 102710216Authorship 102710415Authorship 102710821Authorship 10271119Authorship 1027112134341054Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor a Blockade in Uterine Cancer. Clin Cancer Res. 2021 08 01; 27(15):4449.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor a Blockade in Uterine Cancer.34341055Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MMK, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Targeting Src in Mucinous Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4450.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma.34341056Moreno-Smith M, Lu C, Shahzad MMK, Pena GNA, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Dopamine Blocks Stress-mediated Ovarian Carcinoma Growth. Clin Cancer Res. 2021 08 01; 27(15):4451.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Dopamine Blocks Stress-mediated Ovarian Carcinoma Growth.34341057Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Functional Roles of Src and Fgr in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4452.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Functional Roles of Src and Fgr in Ovarian Carcinoma.34341058Han HD, Mangala LS, Lee JW, Shahzad MMK, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clin Cancer Res. 2021 08 01; 27(15):4453.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles.34341059Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4454.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma.34341060Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Han L, Gershenson DM, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer. Clin Cancer Res. 2021 08 01; 27(15):4455.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.34341061Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJCClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: The Paradoxical Expression of Maspin in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4456.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: The Paradoxical Expression of Maspin in Ovarian Carcinoma.34348992McGuire MH, Dasari SK, Yao H, Wen Y, Mangala LS, Bayraktar E, Ma W, Ivan C, Shoshan E, Wu SY, Jonasch E, Bar-Eli M, Wang J, Baggerly KA, Sood AKMolecular cancer research : MCRGene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.Mol Cancer Res2021-08-04T00:00:002021Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling.Authorship 10273761034367949Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DGFrontiers in oncologyThe Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol. 2021; 11:643815.Front Oncol2021-07-21T00:00:002021The Provocative Roles of Platelets in Liver Disease and Cancer.Authorship 102779913Authorship 10278889Authorship 102796424Authorship 1028094634407412Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AKCell reportsCD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.Cell Rep2021-08-17T00:00:002021CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.34417750Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2021; 2372:157-168.Methods Mol Biol2021-01-01T00:00:002021Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.34391578Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W, Sood AKGynecologic oncologyMEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.Gynecol Oncol2021-08-11T00:00:002021MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.34400004Lutgendorf SK, Ramirez E, Schrepf A, Valentine MC, Charlton M, Zimmerman MB, Goodheart MJ, Zia S, Sood AK, Thaker PHGynecologic oncologyRural residence is related to shorter survival in epithelial ovarian cancer patients. Gynecol Oncol. 2021 10; 163(1):22-28.Gynecol Oncol2021-08-13T00:00:002021Rural residence is related to shorter survival in epithelial ovarian cancer patients.Authorship 10283781434433970Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu XNatureAuthor Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2021 Sep; 597(7875):E6.Nature2021-09-01T00:00:002021Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer.Authorship 10289481034476576Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AKJournal of cancer research and clinical oncologyImmune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. J Cancer Res Clin Oncol. 2021 Dec; 147(12):3545-3555.J Cancer Res Clin Oncol2021-09-02T00:00:002021Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.Authorship 102968027Authorship 10296901034518313Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GBClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.Clin Cancer Res2021-09-13T00:00:002021Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.34518530Wood CA, Han S, Kim CS, Wen Y, Sampaio DRT, Harris JT, Homan KA, Swain JL, Emelianov SY, Sood AK, Cook JR, Sokolov KV, Bouchard RRNature communicationsClinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates. Nat Commun. 2021 09 13; 12(1):5410.Nat Commun2021-09-13T00:00:002021Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates.Authorship 1030242434556331Huang T, Townsend MK, Dood RL, Sood AK, Tworoger SSGynecologic oncologyAntihypertensive medication use and ovarian cancer survival. Gynecol Oncol. 2021 11; 163(2):342-347.Gynecol Oncol2021-09-21T00:00:002021Antihypertensive medication use and ovarian cancer survival.Authorship 103072022Authorship 10307734Authorship 1031042634583979Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AKMolecular cancer therapeuticsRational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361.Mol Cancer Ther2021-09-28T00:00:002021Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.34588424Niu N, Yao J, Bast RC, Sood AK, Liu JOncogenesisIL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis. 2021 Sep 29; 10(9):65.Oncogenesis2021-09-29T00:00:002021IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming.34608736Sasano T, Gonzalez-Delgado R, Mu?oz NM, Carlos-Alcade W, Cho MS, Sheth RA, Sood AK, Afshar-Kharghan VJournal of thrombosis and haemostasis : JTHPodoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J Thromb Haemost. 2022 01; 20(1):104-114.J Thromb Haemost2021-10-15T00:00:002021Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer.Authorship 1031815534670140Liu J, Niu N, Li X, Zhang X, Sood AKSeminars in cancer biologyThe life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Semin Cancer Biol. 2022 06; 81:132-144.Semin Cancer Biol2021-10-17T00:00:002021The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions.Authorship 1032657934711227Ketcher D, Lutgendorf SK, Leighton S, Matzo M, Carter J, Peddireddy A, Karlan BY, Tew WP, Sood AK, Shinn EHBMC women's healthAttributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study. BMC Womens Health. 2021 10 28; 21(1):376.BMC Womens Health2021-10-28T00:00:002021Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study.Authorship 103311727Authorship 103363218Authorship 10340581234772589El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein GCellular signallingCORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2022 Jan; 89:110147.Cell Signal2021-11-09T00:00:002021CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.34731628George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan PCell reportsRNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep. 2021 11 02; 37(5):109934.Cell Rep2021-11-02T00:00:002021RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site.34799731Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AKNature medicineAuthor Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2021 Dec; 27(12):2246.Nat Med2021-12-01T00:00:002021Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.Authorship 1037276835022962Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AKCancer metastasis reviewsOf vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev. 2022 03; 41(1):147-172.Cancer Metastasis Rev2022-01-12T00:00:002022Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.Authorship 103879919Authorship 103913012Authorship 104056215Authorship 104112620Authorship 10415301235216808LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AKGynecologic oncologyClinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.Gynecol Oncol2022-02-23T00:00:002022Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.35094142Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu WJournal of cancer research and clinical oncologyTargeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol. 2022 Apr; 148(4):803-821.J Cancer Res Clin Oncol2022-01-30T00:00:002022Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.35081345Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AKCell reportsEndothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep. 2022 01 25; 38(4):110301.Cell Rep2022-01-25T00:00:002022Endothelial p130cas confers resistance to anti-angiogenesis therapy.35252817Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AKiScienceSpatially resolved transcriptomics of high-grade serous ovarian carcinoma. iScience. 2022 Mar 18; 25(3):103923.iScience2022-02-14T00:00:002022Spatially resolved transcriptomics of high-grade serous ovarian carcinoma.35326647Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Conrads TP, Chen K, Sood AKCancersMolecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers (Basel). 2022 Mar 15; 14(6).Cancers (Basel)2022-03-15T00:00:002022Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer.Authorship 1043517535390531Wu J, Lakomy DS, Fellman BM, Salcedo MP, Sood AK, Jhingran A, Klopp AH, Iyer RB, Jimenez C, Colbert LE, Eifel PJ, Schmeler KM, Lin LLPractical radiation oncologyLongitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):e423-e433.Pract Radiat Oncol2022-04-05T00:00:002022Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment.21806944Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LMGastroenterologyIdentification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37.Gastroenterology2011-07-30T00:00:002011Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.18974154Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli MCancer researchTargeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008 Nov 01; 68(21):9078-86.Cancer Res2008-11-01T00:00:002008Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.21957230Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AKJournal of the National Cancer InstituteSilencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.J Natl Cancer Inst2011-09-28T00:00:002011Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.24045927Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AKCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyImpact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):2102-9.Cancer Epidemiol Biomarkers Prev2013-09-17T00:00:002013Impact of cardiovascular comorbidity on ovarian cancer mortality.24100628Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.Clin Cancer Res2013-10-07T00:00:002013Targeting SRC and tubulin in mucinous ovarian carcinoma.18314475Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AKJournal of the National Cancer InstituteEffect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 05; 100(5):359-72.J Natl Cancer Inst2008-02-26T00:00:002008Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.23360994Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AKNature communicationsSrc activation by ?-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403.Nat Commun2013-01-01T00:00:002013Src activation by ?-adrenoreceptors is a key switch for tumour metastasis.Authorship 1045791735545008Corvigno S, Johnson AM, Wong KK, Cho MS, Afshar-Kharghan V, Menter DG, Sood AKMolecular cancer therapeuticsNovel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles. Mol Cancer Ther. 2022 07 05; 21(7):1067-1075.Mol Cancer Ther2022-07-05T00:00:002022Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles.Authorship 10464062Authorship 10464777Authorship 1046737935626102Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W, Ma Q, Liu J, Sood AK, Afshar-Kharghan VCancersPlatelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers (Basel). 2022 May 19; 14(10).Cancers (Basel)2022-05-19T00:00:002022Platelets Increase the Expression of PD-L1 in Ovarian Cancer.35599168Handley KF, Sood AK, Molin GZD, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming NDGynecologic oncologyFrailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56.Gynecol Oncol2022-05-20T00:00:002022Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.35606067Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KKGynecologic oncologyThe genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567.Gynecol Oncol2022-03-30T00:00:002022The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.Authorship 10474392935688808Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AANature communicationsAuthor Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2022 Jun 10; 13(1):3352.Nat Commun2022-06-10T00:00:002022Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.Authorship 10487581535732127Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AKCell reportsEndothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep. 2022 Jun 21; 39(12):110999.Cell Rep2022-06-21T00:00:002022Endothelial p130cas confers resistance to anti-angiogenesis therapy.Authorship 105130815Authorship 1051522435900623Sharma N, Kaushal A, Yousuf A, Sood A, Kaur S, Sharda REnvironmental science and pollution research internationalGeospatial technology for assessment of soil erosion and prioritization of watersheds using RUSLE model for lower Sutlej sub-basin of Punjab, India. Environ Sci Pollut Res Int. 2022 Jul 28.Environ Sci Pollut Res Int2022-07-28T00:00:002022Geospatial technology for assessment of soil erosion and prioritization of watersheds using RUSLE model for lower Sutlej sub-basin of Punjab, India.35892848Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee SCancersMolecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel). 2022 Jul 23; 14(15).Cancers (Basel)2022-07-23T00:00:002022Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer.Authorship 105995222Authorship 105511510Authorship 106108619Authorship 106082617Authorship 105596571Authorship 105709529Authorship 10575804Authorship 106026517Authorship 10625075Authorship 105451620Authorship 10592726Authorship 1058543336253486Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MCNature cancerTargeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.Nat Cancer2022-10-17T00:00:002022Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.35958027Mateescu B, Jones JC, Alexander RP, Alsop E, An JY, Asghari M, Boomgarden A, Bouchareychas L, Cayota A, Chang HC, Charest A, Chiu DT, Coffey RJ, Das S, De Hoff P, deMello A, D'Souza-Schorey C, Elashoff D, Eliato KR, Franklin JL, Galas DJ, Gerstein MB, Ghiran IH, Go DB, Gould S, Grogan TR, Higginbotham JN, Hladik F, Huang TJ, Huo X, Hutchins E, Jeppesen DK, Jovanovic-Talisman T, Kim BYS, Kim S, Kim KM, Kim Y, Kitchen RR, Knouse V, LaPlante EL, Lebrilla CB, Lee LJ, Lennon KM, Li G, Li F, Li T, Liu T, Liu Z, Maddox AL, McCarthy K, Meechoovet B, Maniya N, Meng Y, Milosavljevic A, Min BH, Morey A, Ng M, Nolan J, De Oliveira Junior GP, Paulaitis ME, Phu TA, Raffai RL, Re?tegui E, Roth ME, Routenberg DA, Rozowsky J, Rufo J, Senapati S, Shachar S, Sharma H, Sood AK, Stavrakis S, St?rchler A, Tewari M, Tosar JP, Tucker-Schwartz AK, Turchinovich A, Valkov N, Van Keuren-Jensen K, Vickers KC, Vojtech L, Vreeland WN, Wang C, Wang K, Wang Z, Welsh JA, Witwer KW, Wong DTW, Xia J, Xie YH, Yang K, Zaborowski MP, Zhang C, Zhang Q, Zivkovic AM, Laurent LCiSciencePhase 2 of extracellular RNA communication consortium charts next-generation approaches for extracellular RNA research. iScience. 2022 Aug 19; 25(8):104653.iScience2022-06-23T00:00:002022Phase 2 of extracellular RNA communication consortium charts next-generation approaches for extracellular RNA research.36423446Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing AGynecologic oncologySelinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.Gynecol Oncol2022-11-21T00:00:002022Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.35965413Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang MMolecular therapy : the journal of the American Society of Gene TherapyBroad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther. 2022 11 02; 30(11):3462-3476.Mol Ther2022-08-13T00:00:002022Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications.36302510Ruiz M, Zhang N, Sood AK, An ZExpert opinion on biological therapyAntibody therapeutics for epithelial ovarian cancer. Expert Opin Biol Ther. 2022 11; 22(11):1379-1391.Expert Opin Biol Ther2022-11-05T00:00:002022Antibody therapeutics for epithelial ovarian cancer.35914489Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein GEBioMedicineCorrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine. 2022 Sep; 83:104194.EBioMedicine2022-07-29T00:00:002022Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304].36077735Stur E, Bayraktar E, Dal Molin GZ, Wu SY, Mangala LS, Yao H, Wang Y, Ram PT, Corvigno S, Chen H, Liang H, Tworoger SS, Levine DA, Lutgendorf SK, Liu J, Moore KN, Baggerly KA, Karlan BY, Sood AKCancersMolecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. Cancers (Basel). 2022 Aug 30; 14(17).Cancers (Basel)2022-08-30T00:00:002022Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.35992327Asare A, Yao H, Lara OD, Wang Y, Zhang L, Sood AKCancer research communicationsRace-associated molecular changes in gynecologic malignancies. Cancer Res Commun. 2022 02; 2(2):99-109.Cancer Res Commun2022-02-17T00:00:002022Race-associated molecular changes in gynecologic malignancies.36251340Lutgendorf SK, Thaker PH, Goodheart MJ, Arevalo JMG, Chowdhury MA, Noble AE, Dahmoush L, Slavich GM, Penedo FJ, Sood AK, Cole SWCancerBiobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression. Cancer. 2022 12 01; 128(23):4157-4165.Cancer2022-10-17T00:00:002022Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.36528667Wong KK, Bateman NW, Ng CW, Tsang YTM, Sun CS, Celestino J, Nguyen TV, Malpica A, Hillman RT, Zhang J, Futreal PA, Rojas C, Conrads KA, Hood BL, Dalgard CL, Wilkerson MD, Phippen NT, Conrads TP, Maxwell GL, Sood AK, Gershenson DMJournal of translational medicineIntegrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. J Transl Med. 2022 12 17; 20(1):606.J Transl Med2022-12-17T00:00:002022Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.36596845Li X, Zhong Y, Zhang X, Sood AK, Liu JOncogeneSpatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. Oncogene. 2023 02; 42(9):665-678.Oncogene2023-01-03T00:00:002023Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells.36239936Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AKJAMA network openClassification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open. 2022 10 03; 5(10):e2236626.JAMA Netw Open2022-10-03T00:00:002022Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.Authorship 106442926Authorship 10645551736824283Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AKiScienceExploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience. 2023 Feb 17; 26(2):106020.iScience2023-01-19T00:00:002023Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer.36835335Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AKInternational journal of molecular sciencesCombination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4).Int J Mol Sci2023-02-15T00:00:002023Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.Authorship 10647211036853778Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu JModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncSOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol. 2023 02; 36(2):100001.Mod Pathol2023-01-09T00:00:002023SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas.Authorship 10652601836884347George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan PCell reportsRNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep. 2023 Mar 28; 42(3):112228.Cell Rep2023-03-07T00:00:002023RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site.Authorship 106568214Authorship 10657051236930815Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AKCancerClinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer. 2023 06 01; 129(11):1672-1680.Cancer2023-03-17T00:00:002023Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.36907533Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RTAmerican journal of obstetrics and gynecologyClinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9.Am J Obstet Gynecol2023-03-11T00:00:002023Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors.Authorship 10662301136948527Foster KI, Handley KF, Glassman D, Sims TT, Javadi S, Palmquist SM, Saleh MM, Fellman BM, Fleming ND, Bhosale PR, Sood AKInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyCharacterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study. Int J Gynecol Cancer. 2023 06 05; 33(6):937-943.Int J Gynecol Cancer2023-06-05T00:00:002023Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.Authorship 106772025Authorship 10680473Authorship 10681423237031740Liu Y, Ahumada AL, Bayraktar E, Schwartz P, Chowdhury M, Shi S, Sebastian MM, Khant H, de Val N, Bayram NN, Zhang G, Vu TC, Jie Z, Jennings NB, Rodriguez-Aguayo C, Swain J, Stur E, Mangala LS, Wu Y, Nagaraju S, Ermias B, Li C, Lopez-Berestein G, Braam J, Sood AKJournal of controlled release : official journal of the Controlled Release SocietyEnhancing oral delivery of plant-derived vesicles for colitis. J Control Release. 2023 05; 357:472-483.J Control Release2023-04-20T00:00:002023Enhancing oral delivery of plant-derived vesicles for colitis.37023452Conley AB, Fournier KF, Sood AK, Frumovitz MObstetrics and gynecologySecondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer. Obstet Gynecol. 2023 05 01; 141(5):1019-1023.Obstet Gynecol2023-04-05T00:00:002023Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer.37100807LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AKNature communicationsOvercoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun. 2023 04 26; 14(1):2407.Nat Commun2023-04-26T00:00:002023Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.Authorship 107216613Authorship 10737998Authorship 107275515Authorship 1073705637311055Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SAThe oncologistA Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11; 28(12):1100-e1292.Oncologist2023-12-11T00:00:002023A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.37274180Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AKCell reportsEndothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep. 2023 03 28; 42(3).Cell Rep2023-03-28T00:00:002023Endothelial p130cas confers resistance to anti-angiogenesis therapy.37326992Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, Shimada M, Machida H, Mikami M, Klar M, Roman LD, Wright JD, Sood AK, Gershenson DMJAMA network openUptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas. JAMA Netw Open. 2023 06 01; 6(6):e2318602.JAMA Netw Open2023-06-01T00:00:002023Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.37218522Gajjela CC, Brun M, Mankar R, Corvigno S, Kennedy N, Zhong Y, Liu J, Sood AK, Mayerich D, Berisha S, Reddy RThe AnalystLeveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer. Analyst. 2023 Jun 12; 148(12):2699-2708.Analyst2023-06-12T00:00:002023Leveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer.Authorship 1075010937478190Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, Peng G, Westin S, Sood AK, Liu JScience advancesTargeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv. 2023 07 21; 9(29):eadf7195.Sci Adv2023-07-21T00:00:002023Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.Authorship 107842510Authorship 10771191237591609Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DMInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyLow-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 09 04; 33(9):1331-1344.Int J Gynecol Cancer2023-09-04T00:00:002023Low-grade serous ovarian cancer: expert consensus report on the state of the science.37587850Telles R, Zia S, Greteman BB, Thaker PH, Penedo F, Charlton ME, Goodheart MJ, Armer JS, Noble A, Sood AK, Lutgendorf SKJournal of psychosocial oncologyWell-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic. J Psychosoc Oncol. 2023 Aug 17; 1-16.J Psychosoc Oncol2023-08-17T00:00:002023Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic.Authorship 10826261037909041McGrail DJ, Li Y, Smith RS, Feng B, Dai H, Hu L, Dennehey B, Awasthi S, Mendillo ML, Sood AK, Mills GB, Lin SY, Yi SS, Sahni NCell reports. MedicineWidespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins. Cell Rep Med. 2023 11 21; 4(11):101255.Cell Rep Med2023-10-30T00:00:002023Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins.Authorship 108321324Authorship 10831101237940695Rodriguez-Aguayo C, Del C Monroig P, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein GCell discoveryAuthor Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2023 Nov 08; 9(1):111.Cell Discov2023-11-08T00:00:002023Author Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.37923835Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AKNPJ precision oncologyIn situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol. 2023 Nov 03; 7(1):115.NPJ Precis Oncol2023-11-03T00:00:002023In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy.Authorship 1084230938009662Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AACancerRandomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.Cancer2023-11-27T00:00:002023Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.Authorship 108559618Authorship 10852211038081436Lutgendorf SK, Telles RM, Whitney B, Thaker PH, Slavich GM, Goodheart MJ, Penedo FJ, Noble AE, Cole SW, Sood AK, Corn BWBrain, behavior, and immunityThe biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients. Brain Behav Immun. 2024 02; 116:362-369.Brain Behav Immun2023-12-09T00:00:002023The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients.38118413Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni NCell reports. MedicinePRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med. 2023 12 19; 4(12):101326.Cell Rep Med2023-12-19T00:00:002023PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.Authorship 10866901438191019How JA, Legarreta AF, Handley KF, Fellman B, Foster KI, Glassman D, Vuttaradhi VK, Brodsky AL, Lawson B, Frumovitz M, Westin SN, Ramondetta LM, Gershenson DM, Sood AK, Hillman RTAmerican journal of obstetrics and gynecologySerial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 Jan 06.Am J Obstet Gynecol2024-01-06T00:00:002024Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.Authorship 108785122Authorship 1087926338250760Vo D, Liu Y, Sood AK, Rezvani K, Jazaeri AA, Liu JCancer biomarkers : section A of Disease markersEGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma. Cancer Biomark. 2023 Dec 28.Cancer Biomark2023-12-28T00:00:002023EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.38279277Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, Vu TC, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AKInternational journal of molecular sciencesEphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).Int J Mol Sci2024-01-20T00:00:002024EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.Authorship 1088309938309031Telles R, Zimmerman MB, Thaker PH, Slavich GM, Ramirez ES, Zia S, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SKGynecologic oncologyRural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients. Gynecol Oncol. 2024 Feb 02; 184:139-145.Gynecol Oncol2024-02-02T00:00:002024Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients.Authorship 1089625238415273Aris M, Sood AK, Zaslavsky AFrontiers in cell and developmental biologyEditorial: Platelets in tumor biology: from molecular mechanisms to clinical applications. Front Cell Dev Biol. 2024; 12:1373463.Front Cell Dev Biol2024-02-13T00:00:002024Editorial: Platelets in tumor biology: from molecular mechanisms to clinical applications.Authorship 10905538Authorship 1090436838463509Reihanisaransari R, Gajjela CC, Wu X, Ishrak R, Corvigno S, Zhong Y, Liui J, Sood AK, Mayerich D, Berisha S, Reddy RArXivRapid hyperspectral photothermal mid-infrared spectroscopic imaging from sparse data for gynecologic cancer tissue subtyping. ArXiv. 2024 Feb 28.ArXiv2024-02-28T00:00:002024Rapid hyperspectral photothermal mid-infrared spectroscopic imaging from sparse data for gynecologic cancer tissue subtyping.38471508Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AAMed (New York, N.Y.)Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Mar 07.Med2024-03-07T00:00:002024Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.Authorship 1091435838513238Lee MW, Anderson ZS, Girma AM, Klar M, Roman LD, Carlson JW, Wright JD, Sood AK, Matsuo KObstetrics and gynecologyDiagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma. Obstet Gynecol. 2024 Mar 21.Obstet Gynecol2024-03-21T00:00:002024Diagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1InstructorInstructor21720365Cancer Genome Atlas Research NetworkNatureIntegrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29; 474(7353):609-15.Nature2011-06-29T00:00:002011Integrated genomic analyses of ovarian carcinoma.24799285Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath DMolecular systems biologyMetabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014 May 05; 10:728.Mol Syst Biol2014-05-05T00:00:002014Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.24952408Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AKGynecologic oncologySummary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9.Gynecol Oncol2014-07-01T00:00:002014Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.24970481Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MCCancer researchDefinition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35.Cancer Res2014-06-26T00:00:002014Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer.